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Abstract 
Context: The incidence of Type II Diabetes Mellitus (DM) is rapidly expanding in the 
United States. Cardiovascular disease (CVD) remains the leading cause of death for 
people with DM. Since a systematic review had not be done to assess ifDM is a CVD or 
coronary heart disease (CHD) risk equivalent for future CHD events the most recent 
guidelines from the National Cholesterol Education Panel, the Adult Treatment Panel III 
(ATP-III) were made based on a series of three studies. The ATP-III recommended that 
all people with DM be treated as (CHD) risk equivalents. 
Objective: To review the literature systematically to answer the question "Is DM a 
substantial CHD risk equivalent for hard CVD events?" and to further analyze this 
question by answering a series of sub-questions. 
Data Sources: We searched MEDLINE including the clinical queries option through 
December 17,2007 for English language articles containing the MESH phrases 
"Arterioscleorsis" or "Myocardial Ischemia/epidemiology" or "Myocardial 
Ischemia/prevention and control" AND "Diabetes Mellitus". We also hand searched 
bibliographies of relevant articles and files of experts in the field. 
Study Selection: Studies were included if they were in conducted in western populations, 
had at least a 5 year follow-up period, measured clinical outcomes of CVD (not 
intermediate factors), and answered our primary question or one of our sub-questions of 
the primary question by allowing direct comparison of patients with DM and no CVD to 
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those with CVD but no DM. Admissible study designs included cohort studies, 
systematic reviews, meta-analyses, and controlled trials. Studies were independently 
critically appraised by two reviewers with discrepancies adjudicated by a third reviewer. 
Studies that were of adequate internal and external validity were included in the results. 
Data extraction: Two reviewers independently abstracted the relevant data from the 
included studies and entered them into evidence tables. These tables were checked 
against each other and combined into a single table. 
Data synthesis: There is little data comparing the risk of nonfatal CHD events between 
DM and prior CHD/CVD. Mixed effects were noted when answering the question of 
whether or not DM is a CHD risk equivalent for future CHD mortality or CVD mortality. 
Most studies suggested that prior MI conferred a higher risk for future CVD events than 
did DM. When compared to men, DM seemed to confer a higher risk in women for 
future CHD than did prior MI. DM also seemed to confer higher risks for CHD mortality 
in relation to the risk ofMI as a women aged and in people with a long duration ofDM. 
Equivalent risk factors in populations of people with DM compared to those with prior 
MI did not seem to change the risk equivalency for future CHD morality when compared 
to the overall unstratified analysis. We also found that there is inadequate research to 
show how the presence of other markers of CVD in people with DM changes their risk 
for future CHD events in relation to those with DM but without CVD or those without 
DM but with prior CHD 
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Conclusion: DM is not a universal CHD risk equivalent for future CHD mortality. All 
patients with DM should not be treated to the stringent LDL cutoffs used for people with 
prior CHD. Those at low risk (young, short duration of diabetes, few other risk factors, 
etc.) should be treated based on their absolute risk calculation for future CHD which 
takes into account an individual's clinical scenario. 
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Introduction 
Diabetes Mellitus (DM) is a established contributor to the population health 
burden of cardiovascular disease* (CVD). CVD remains the leading cause of death for 
people with DM with about 65% dying from heart disease or stroke.[!] Current data 
estimate that 7 percent of the American population, 20.8 million people, have diabetes.[!] 
The vast majority of Americans with DM, 90-95%, have Type 2 DM.[l] 
Due to the high prevalence of Type 2 DM and its association with other 
cardiovascular risk factors, it is most commonly studied when considering the overall 
CVD risks ofDM. Type 2 DM is commonly accompanied by the triad of hyperglycemia, 
insulin resistance, and excess free fatty acids which leads to dyslipidemia.[2, 3] Of 
interest, the pattern of dyslipidemia seen in Type 2 DM is particularly atherogenic. This 
"diabetic dyslipidemia" consists of high triglycerides, low HDL, and normal to increased 
LDL with a high percentage of small dense LDL.[2-4] Thus, Type 2 DM patients have a 
higher risk of CVD events when compared to a non-diabetic with the same LDL 
cholesterol level. [5] Furthermore, it is well researched that patients with Type 2 DM 
have a worse prognosis following a myocardial infarction (MI) than do persons without 
DM. [6, 7] 
In response to a small series of articles [8-1 0] and the presence of increased 
morbidity and mortality after MI in patients with Type 2 DM, the National Cholesterol 
Education Panel (NCEP) of the National Heart, Lung, and Blood Institute updated the 
Adult Treatment Panel (ATP) guidelines raising DM to the status of a cardiovascular 
heart disease (CHD) risk equivalent for future CHD events as opposed to classifying it as 
• CVD ~ Heart Disease and Stroke 
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a risk factor.[ 4] This reclassification scheme automatically places all patients with DM 
into the highest CHD risk category requiring the most aggressive treatment cutoffs (LDL 
goal <100, consider drug therapyif~130) irrespective of a given individual's risk factors. 
This reclassification has had profound implications on the use of cholesterol lowering 
medications. 
The most recognized study of the three studies used to frame the NCEP guidelines 
was done by Haffner et al. comparing mortality from MI in subjects with type 2 DM 
without prior MI and non-diabetics with prior MI.[8] Haffuer and his colleagues found 
that the adjusted hazard ratio (adjusted for age, sex, total cholesterol, hypertension, and 
smoking) for death from MI for type 2 DM subjects without prior MI was not 
significantly different compared to that of non-diabetic subjects with prior MI (HR 1.2 
95% CI 0.6-2.4, referent group was non-diabetic subject with prior MI).[8] Although this 
is a well conducted study, there are four key worries that question the wisdom of only 
using this article to form recommendations. These are: potential residual confounding, 
small numbers of outcome events leading to wide confidence intervals, selecting a 
population with high rates of mortality due to CHD, and narrowing the outcome to only 
mortality from CHD events as opposed to measuring all CHD events. 
Excluding Haffuer's original article, the other two studies did not directly address 
whether DM is a CHD risk equivalent.[9, 1 0] The second Haffuer article measured 
carotid artery intima-media thickness, an intermediate outcome which is less reliable than 
directly answering the primary question.[9] ln the third study all of the patients with DM 
also had either unstable angina or a non-Q-wave MI.[lO] Given that unstable angina and 
non-Q-wave MI are both considered CHD events by the NCEP, the subjects with DM in 
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this study all qualify as having prior CHD and thus are placed in the highest risk category 
irrespective of their DM status.[ 4] 
The authors of the ATP III also cite a study of elderly Australians showing that 
DM was not a CHD risk equivalent when compared with prior CHD.[4, 11] At the time 
A TP recommendations were written, the panel chose to base their recommendations on 
the assertion that DM is a CHD risk equivalent due to the paucity of data showing a lack 
of equivalence and the strength of Haffi1er's article. However, since the publication of the 
A TP III guidelines in 2002 other studies have been published that, like the study 
mentioned in the previous paragraph, address whether NIDDM represents a CHD risk 
equivalent for future CHD events. 
To implement the most appropriate interventions, clinical practice guidelines, 
such as the ATP guidelines, should be based on an unbiased systematic review of the 
literature. [12, 13] However, to date a systematic review assessing if Type 2 DM is a 
CHD risk equivalent for future CHD events has not been done. This paper proposes to 
look carefully and systematically at the question of whether DM is a substantial CHD risk 
equivalent for hard CHD events (including nonfatal MI and CHD mortality). 
This paper will also examine multiple complexities of the primary question that 
may lead to different answers. For example, how does the risk comparison change if the 
definition of prior CHD is expanded to include other conditions such as angina? In order 
words, if we expand the exposure variable to include other measures of CV disease 
besides MI, does the answer to whether or not DM is a CHD risk equivalent change? 
If we broaden the outcome measure to include all "hard" CVD events (MI, sudden 
cardiac death, stroke, sudden vascular death, symptomatic PVD) will we get a different 
7 
answer than using the more narrow CHD mortality as our outcome? Does the answer to 
our primary question differ if we expand the outcome to include other cardiovascular 
outcomes such as CV A? It was previously noted in data from the United Kingdom 
Prospective Diabetes Study (UKPDS), that patients with type 2 DM are at higher absolute 
risk of having a future MI event (14.7-17.4/1000 patient/years) than they are of having a 
future CVA event (5.0-5.8/1000 patient/years). [14] 
Does the presence of established other vascular disease, such as PVD or CV A, in 
the diabetic cohorts change the outcome of our question? Using data from the 
Framingham study, Abbott et al. [15] found that diabetic patients that had peripheral 
arterial findings (carotid bruits, femoral bruits, or non-palpable pedal pulses) had an 
increased risk for other major CVD outcomes as compared to those with diabetes only. 
More recently, Norman et al. [16] used the ankle-brachial index (ABI) measurement to 
illustrate the concept of using PAD as a marker for atherosclerotic vascular disease in the 
type 2 diabetic population. In this case the authors found patients having an ABI of <90 
and diabetes were at higher risk of cardiac death than those with only diabetes.[16] 
Does age of the patient matter? Most elderly people already have some degree of 
atherosclerosis contributing to a high risk for CHD events, whereas younger people are 
generally healthy and at low risk for CHD. Therefore, is it possible that in older people 
DM along with age associated risk causes CHD risk in a person with DM to equal that of 
a person with prior MI? Whereas, in a younger people the risk for CHD events is so low 
that those with prior MI only will have very serious disease such that in young people 
having DM only does not lead to CHD risk equivalence? 
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Does the answer to the primary question differ between genders? Comparing the 
Women's Health Study [17] to the Physicians Health Study [18] gives us some insight 
into the fact that the myocardial ischemia behaves differently in men compared to women. 
While the low-dose alternate day aspirin therapy arm of the PHS had to be terminated 
early due to aspirins' profound effects on the primary prevention ofMI [18], aspirin had 
no significant effect on primary prevention of MI in the all female WHS [ 17]. 
Does the duration or control of a person's DM change the answer to the overall 
question? For instance, is risk determined by the overall glycemic load, how high the 
blood glucose has been over how long it has been high. 
This primary question and its complexities are important because if we find that 
Diabetes Mellitus is not an independent CHD risk equivalent then by choosing to 
selectively, rather than universally, treat patients with DM it will be possible to both 
reduce harmful side effects experienced from using lipid lowering medications in 
situations where they provide little effect and to increase the cost effectiveness of using 
lipid lowering therapy in the population of patients with Type 2 DM. 
We will examine whether these questions are answerable with the current 
evidence. If they are answerable we will evaluate current recommendations to see if they 
should be updated and changed given new data; if the results are inconclusive we will 
attempt to identify what data are needed to further our knowledge as to how to best treat 
Type 2 DM patients. 
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Methods 
Focused Question and Inclusion/Exclusion Criteria 
To direct our literature search, we developed a primary focused question: 
What is the 5-l 0 year risk of CHD events in people with DM who do not have a 
history of prior MI compared with the 5-10 year risk of CHD events in people without 
DM who have had a prior MI. We defined CHD events as "hard" CHD events including 
nonfatal MI, and cardiac death. 
We also considered several a priori-stated sub-questions within this overall 
question: 
I) Does the answer to the primary question differ if the prior MI 
definition of exposure is expanded to include other types of CVD (such 
as angina, stroke, etc)? 
2) Does the answer to the primary question differ if the outcome is 
expanded to include hard CVD events (including MI, CV A, symptomatic 
PVD, and sudden cardiac/vascular death)? 
3) Does the answer to the primary question differ among prior diabetics 
who do or do not have symptomatic CVD other than MI (e.g. angina, 
TlA, CABG, previous CVA, symptomatic claudication)? 
4) Does the answer to the primary question differ among people at high 
vs.lower CVD risk (e.g., higher number ofCVD risk factors)? 
5) Does the answer to the primary question differ among men vs. women 
6) by age 
7) or by duration or control of diabetes? 
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We chose to focus our study on western populations in the age range of30-74. 
Given that we want to direct our question to western populations, to avoid heterogeneous 
confounding factors between studies, such as cultural influence, that may change CVD 
risk between populations and would reduce the internal validity of our review we chose 
to limit included studies to only those that were conducted in western populations. We 
further chose to limit our review to studies that only included persons between the ages of 
30-74 because that is the population that the most common clinically used CHD risk 
calculator, the Framingham CHD Risk Calculator, is based on.[l9) We also required that 
each study must compare our two groups of interest, those patients with DM without 
prior MI and those patients with prior MI and without DM. Given the inability to control 
and standardize a cohort study, to obtain the "true" answer to our question the two groups 
of interest must be chosen and tested under the same conditions, otherwise the risk for 
selection and measurement biases skewing our answer would be too great Also, within a 
cohort study (given that the populations cannot be randomized to distribute potential 
confounders evenly between the two groups of interest), it is imperative that the studies 
used in this review assess CVD risk factors among the two groups of interest using 
proper statistical adjustment 
We chose to only include hard clinical CHD events as our outcome measure for a 
couple of reasons. First, we wanted to directly answer the question we were asking rather 
than measure an intermediate outcome, such as angina or coronary artery stenosis, to 
eliminate the case-specific heterogeneity in detection, progression, and treatment of 
intermediate outcomes and their subsequent influence on our final outcome. Secondly, 
measurement of "hard" health outcomes are more defined and absolute, that is they are 
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easier to measure because they are more clinically apparent making them easier to 
measure and harder to overlook. Since CVD is a chronic condition, we wanted to 
examine risk over a reasonable time period; thus we chose to limit our search to studies 
that had a minimum follow-up period of 5 years. 
Regarding study design we were primarily looking for systematic reviews and 
cohort studies because they represent the best fit study designs for our question. 
However we used a more comprehensive search to assure that we did not miss any 
important randomized controlled trials or meta-analyses. We excluded cross sectional 
studies given their inability to establish prognosis and thus risk. Due to practical reasons 
we were forced to include only studies that were published and written in English. We 
also chose to eliminate any studies that had fatal flaws in internal validity given that we 
could not be convinced of their conclusions. Furthermore, we required adequate 
description of the study to assess external validity so that we were able to maintain a 
degree of homogeneity between the study targets and thus come to a valid conclusion. 
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Table 1. Inclusion and Exclusion Criteria for Selecting Admissible Evidence 
Primary Focused Question: "What is the 5-10 year risk of CVD events in people with 
DM who do not have a history of prior MI, compared with the 5-10 year risk of CVD 
events in people without DM who have had a prior Ml?" 
Selection Criteria Eligibility Criteria 
Populations - Allows comparison of the CVD outcomes 
of two groups: people with DM without a 
history of prior MI and people without DM 
who have a history ofMI 
- Includes information about CVD risk 
factors and treatment of risk factors; allows 
adjustment of rates of the two groups to 
make them comparable with regard to such 
risk factors as BP, lipids, use of A SA. 
- Western Societies 
-Ages 30-74 
Outcome - Follow-up of at least 5 years 
- Accurate and reliable measurement of 
CVD events 
- Must have clinical outcomes of CVD 
events: excluded studies with only 
intermediate outcomes (e.g. Carotid Artery 
Stenosis) 
Study Design - Cohort Studies 
- Systematic Reviews 
- Meta-Analyses 
- Controlled Trials 
- Limits: English language 
- Only articles in print 
-Fair and Good quality (internal validity) 
studies only 
- Provides information to assess external 
validity 
Search Strategy 
We searched MEDLINE, including the clinical queries option which 
automatically searches the Cochrane library, for eligible studies (see Table 2). Our 
search included all studies published in English up to December 17, 2007. We recovered 
2081 abstracts. We only searched MEDLINE due to the fact that we did not have access 
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to other medical search engines, which may limit our ability to catch all relevant studies 
with our search. Thus, we attempted to increase the sensitivity of the search by querying 
experts and hand searching bibliographies of pertinent articles. Our initial search strategy 
was as sensitive as possible, using the overarching MeSH term of "Myocardial Ischemia". 
We found that we could not use the MeSH term "recurrence" to define our population of 
people without DM but with prior MI due to the fact that it greatly limited the number of 
studies and did not include studies referred to us from experts. Since we were not able to 
narrow the search using "recurrence", given the large number of studies published solely 
on Myocardial Ischemia we were forced to abbreviate the search term to the two 
subcategories, "epidemiology'' and "prevention and control". We determined that these 
two subcategories of Myocardial Ischemia were appropriate by consulting librarians and 
experts, subsequently confirming that articles referred to us from experts were found 
using these terms. It is possible that by using the subcategories we missed important 
studies, however given the practical constraints of conducting the study we felt that this 
was the best case approach. It is important to note that we linked our Myocardial 
Ischemia subcategories to Diabetes Mellitus using the term AND. Since we required that 
all studies directly compare people with DM but with no MI to those that had MI but no 
DM we were able to eliminate many unnecessary articles buy using AND instead of OR. 
We were also forced to limit to only published articles that were written in English. Both 
of these limits also increase our potential for retrieval bias thus increasing the chance that 
we missed important articles. To examine our sub-questions we only modified our search 
terms by adding the MeSH term "arteriosclerosis" as all other sub-questions should be 
captured by the search terms for the main search question. 
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Table 2 Final Search strategy 
Populations Pubmed Search terms: "Diabetes 
Mellitus"[MeSH] AND "Myocardial 
Ischemia/prevention and control"[MeSH] or 
"Myocardial 
Ischemia/epidemiology"[MeSH] 
Outcome Pubmed search terms: "Myocardial 
Ischemia/prevention and control"[MeSH] 
OR "Myocardial 
Ischemia/epidemiology"[MeSH] 
Study Design Pubmed search terms: "cohort studies", 
"Clinical Trial"[ptyp ], "systematic"[ sb ]. 
Full search : ("Arteriosclerosis"[MeSH] OR ("Myocardial Ischemia/epidemiology"[MeSH] 
OR "Myocardial Ischemia/prevention and control"[MeSH]) AND "Diabetes 
Mellitus"[MeSH] AND and cohort studies AND (English[lang])) OR 
("Arteriosclerosis"[MeSH] OR ("Myocardial Ischemia/epidemio1ogy"[MeSH] OR 
"Myocardial Ischemia/prevention and control"[MeSH]) AND "Diabetes Mellitus"[MeSH] 
AND (Clinical Tria1[ptyp]) AND (English[lang])) OR ((("Arteriosclerosis"[MeSH] OR 
("Myocardial Ischemia/epidemiology"[MeSH] OR "Myocardial Ischemia/prevention and 
control"[MeSH]) AND "Diabetes Mellitus"[MeSH] AND (English[1ang]))) AND 
systematic[ sb]) 
Identifying Pertinent Articles 
See Table 3 for a numerical outline of the methods used to identify articles that 
were abstracted for data. Once the abstracts from all the articles were obtained (2,081), 
the two primary authors divided the abstracts and independently reviewed them, using the 
inclusion/exclusion criteria to categorize them as "pertinent", "possibly pertinent", or "not 
pertinent". The 1,951 studies classified as "not pertinent" were reviewed by the other 
author before discarding them. If the two authors disagreed on discarding an abstract, it 
was carried forth for further review pending retrieval of the full text article. Full text 
articles of the 130 pertinent and possibly pertinent articles were then compiled in an 
Endnote library, read, and re-categorized by the two primary authors into articles that 
were directly addressed the primary question (18) and articles that may be useful for 
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background or were no longer useful (112). None of 130 pertinent and possibly pertinent 
articles were discarded. 
Data Abstraction 
The two primary authors independently appraised the internal validity of the 
studies that met all eligibility requirements and directly addressed the focused question. 
We began the data abstraction process by cutting and pasting the MEDLINE abstract into 
a table, which we subsequently filled in with all of the required data needed for the 
review, see Figure I. We compared the main study question of each article to what was 
done in the study and the final conclusion of the study. If the study did not address the a 
priori initial question the study was considered to have a fatal flaw and thus excluded 
from the review. We then examined each article for the three main types of biases, 
selection, measurement, and confounding. We examined each category of bias within the 
article for the presence of "fatal flaws", defined as an unforgivable potential for bias in 
any of the three categories. If no fatal flaws were found we ranked each category of bias 
on a scale from I-III, III being the worst. 
We examined the study for selection bias, including who was invited to 
participate in the study, ifboth groups were obtained from the same source population, 
how many invited participants actually participated in the study and how the groups were 
maintained throughout the study, including number of drop-outs/loss to follow-up in each 
group. Measurements of both exposure, interventions (if applicable), outcomes, and 
potential confounders were considered next. Measurements were assessed to determine if 
they were valid (accurate), reliable (reproducible), and applied to all study participants 
equally. Confounders were considered if they were differentially related to one of the 
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study groups, the outcome, and were not a causal intermediate in the pathway from the 
exposure to the outcome. Proper analysis techniques were examined in the context of the 
design of the study, controlling for confounding, and appropriate handing of data when 
loss to follow-up or dropout occurred. If the study was a "negative" study, we examined 
it to determine the power of the study to detect a difference when a difference is actually 
present. If the power of the study was extremely low, as evidenced by a very large 
confidence interval, it was considered to have a fatal flaw and excluded from the review. 
Studies with moderate sized confidence intervals were included in the review. 
The internal validity of these studies was graded based on the scheme developed 
by the United States Preventive Services Task Force.[20) A "good" study is considered 
to adequately meet all criteria relevant to the study design, a "fair" study is one that does 
not meet all criteria but also does not include any fatal flaws, a "poor" study is one that 
includes a fatal flaw.[20) A fatal flaw is considered if there is a high probability for any 
of the types of biases (selection, measurement, confounding), if the analysis techniques 
are not appropriate, or the study otherwise had a serious methodological flaw that would 
inhibit the study from correctly answering its question. Ifthere was disagreement 
between the two primary authors about grading the internal validity of a study, a third 
investigator reviewed the study and the disagreement was decided by discussion among 
all three investigators. 
If an article was found that addressed the question but was, by consensus of all 
three investigators, of poor quality, it was excluded from the review. All studies that met 
eligibility criteria and were of good or fair internal validity and had adequate information 
to assess external validity were included in the evidence table found in the results section. 
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Figure 1: Critical Appraisal Criteria 
Table 3 Flow Chart of Articles Identified to arrive at those included 
Number of Articles 
Abstracts Identified 2081 
Pertinent/Possibly pertinent 130 
No 1951 
Full text reviewed 130 
Pertinent 18 
Not pertinent to primary question (many were 112 
backgronnd articles) 
Articles on sub-guestion#2 found from other sources 
Citation Review (later excluded due to broad outcomes) I [21] 
Articles on nrimary guestion found from other 
sources 
Expert Files I [22] 
Total articles addressing 12rimar.y guestion 19 
Excluded for short follow-up 1[23] 
Excluded not direct comparison I [24] 
Papers with poor quality 4 [II, 22, 25, 26] 
Not used for primary question: broad CHD exposure 3[27-29] 
Final Number 10 
Funding 
This review was not funded by an outside funding agency nor do any of the 
authors have connections with outside funding agencies, 
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Results 
In Appendix A we included detailed summary tables for all studies that addressed 
our primary question. Those tables include abstracted data on the following topics: 
- Internal validity and external validity grading 
- Population selection method and demographics 
- Follow-up length 
- Measurements 
- Statistical analysis and adjustments used 
- Power estimate of the study, if applicable 
- Summary of results by outcome (CHD events, CHD mortality, CVD events, 
CVD, mortality, and Overall mortality). 
For studies that addressed our primary question but were considered to be of poor 
quality, the above data (with the exception of results, power, and external validity) along 
with the reasons for the study being considered poor and thus not used to draw formal 
conclusions, can also be found in Appendix A. 
Our results are structured to parallel our original question and its division into 
sub-questions. Overall results applicable to the question of whether or not DM is a 
cardiovascular risk equivalent for future CHD events will be presented first, followed by 
results divided by the sub-questions: 1) Exposure expanded to include other types of 
CVD. 2) Outcome expanded to include hard CVD events 3) Diabetics who do versus 
those who do not have symptomatic CVD other than MI 4) High versus lower CVD risk 
5) Division by demographic factors including gender, 6) age, and 7) glycemic load. 
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Summary data from studies meeting inclusion criteria addressing either our main 
question or a sub-question can be found within the body of the results section of the paper. 
Of note, studies may be included more than one table if they address both our main 
question and one or more sub-questions. 
Primary Question: Do patients with prior DM only have the same risk for future 
hard CHD events as those with prior MI only? 
We identified ten studies that both answered this question and met our inclusion 
criteria [8, 30-38). All of the studies received a final internal validity rating of"Fair" and 
external validity rating of "Fair" or "Good" for the populations that they studied. Given 
that no studies were ranked overall as "Good", a single analysis of all studies addressing 
the question will be done as opposed to a stepwise analysis separating the Good from the 
Fair studies. Outcome data regarding CHD events vs. CHD mortality will be broken 
down into two separate groups of tables to allow for easier interpretation. One study, Lee 
et a!. 2004 [3 8], did not separate these outcomes and thus will be presented as a combined 
outcome measure. Results and outcomes measure from these studies can be found in 
Tables 4-6. Also if a study reported a relative risk or hazard ratio comparing MI in 
reference to DM, the inverse was also given in the results column of the table to show the 
relative risk ofDM in reference to MI in order to allow for easier comparison between 
studies. 
Studies that report effects when the outcome is defmed as CHD events 
Only one study, conducted in men by Wannamethee eta!. 2004 [30], reported 
separate outcome measures for CHD events comparing people with prior DM to those 
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with prior MI (Table 4). Of note, this study calculated the risk of CHD/CVD events and 
CHD/CVD mortality in men with DM, prior MI, and angina pectoris, therefore results 
from this study will also be discussed in sub-questions 1 and 2. They defined CHD 
events as non-fatal MI as outlined by the second edition of the WHO criteria [30). They 
found that the risk for future non-fatal MI is lower in men with only DM as compared to 
those with only prior MI, RR MI vs. DM = 1.59 (1.09-2.31 ). 
Table 4. Risk for future CHD events comparing patients with prior DM only to those with 
prior MI only 
The risk for future CHD events is higher in people with DM only as compared to those with only 
prior MI. 
Study (population) Risk measurement [inverse) Definition of outcome 
No studies Not applicable Not applicable 
The risk for future CHD events is equivalent in people with DM only as compared to those with only 
prior MI. 
Study (population) Risk measurement [inverse] Definition of outcome 
No studies Not applicable Not applicable 
The risk for future CHD events is lower in people with DM only as compared to those with only prior 
MI. 
Study (population) Risk measurement [inverse] Definition of outcome 
Wannamethee 2004 (men)[30] MI vs. DM: RR- 1.59 (1.09- Nonfatal MI as defmed by WHO 
2.31) [0.63 (0.43-0.92)] criteria 
Studies that report effects when the outcome is defmed as CHD events and CHD 
mortality 
Lee eta!. 2004 [38], in a nine year population based follow-up study of men and 
women, found that when a combination of CHD events and CHD mortality is considered 
the outcome, people with only prior MI had a higher risk of future adverse outcomes than 
did people with prior DM only, RR = 1.86 (1.35-2.56). They defined CHD events as 
definite or probable hospitalization for MI as identified through annual contact with 
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participants and a search of local hospital discharge records. [3 8] Of note, these 
participants may be of lower risk than a true general population because the authors 
excluded people with prior CV surgery, coronary angioplasty, stroke, or cancer. [38] 
Table 5. Risk for future "hard" CHD events (nonfatal CHD events+ CHD mortality) 
t t "th DM I t th "th MI I companng pa ten s WI pnor on yo osew1 tpnor on y. 
The risk for future "hard" CHD events is higher in people with DM only as compared to those with 
only prior MI. 
S!udy (population) Risk measurement [inverse] Definition of outcome 
No s!udies Not applicable Not applicable 
The risk for future "hard" CHD events is equivalent in people with DM only as compared to those 
with only prior MI. 
S!udy (population) Risk measurement [inverse] Definition of outcome 
No sluclies Not applicable Not applicable 
The·risk for future "hard" CHD events is lower in people with DM only as compared to those with 
only prior MI. 
S!udy (population) Risk measurement [inverse] Definition of outcome 
Lee eta!. 2004 [38] MI vs. DM: RR ~ 1.86 (1.35-2.56) definite or probable hospitalization 
[0.54 (0.39-0.74)] for MI or defmite fatal CHD 
Studies that report effects when the outcome is defined as CHD morality 
There were many more studies that used CHD mortality instead of CHD events as 
their final outcome, likely due to the ease and accuracy of measuring death as compared 
to measuring an event. Their results are summarized in Table 6. Many studies are 
represented more than once within the table because they reported outcomes by dividing 
their overall population into two or more groups based on demographic characteristics. 
Given that the results of the different studies were quite heterogeneous a meta-analysis of 
the outcomes is not appropriate. A narrative analysis will be presented instead. 
In two studies, [31, 32], the authors found patients with DM to be at higher risk 
for future CHD mortality than those with only prior MI in one of their subpopulations. 
Six studies, including the original Haffner article [8], for a total of nine subgroups agreed 
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that in at least one of their population subdivisions prior DM is a risk equivalent to prior 
MI when considering CHD death as the outcome. [30, 32-35] Five studies [31, 33, 34, 
36, 37] totaling eight subgroups found that participants with DM had a lower risk of CHD 
death than did those with prior MI. 
Hu 2005 [31] in their Finnish population study found that women with MI at 
baseline had a HR of 0.57 (0.39-0.82) when comparing them to women with DM at 
baseline over a mean follow-up period of 12 years. However, they did not obtain the 
same results when they compared participants with either baseline or incident MI in 
reference to their other three equivalent subpopulations, women with incident DM (HR = 
1.65 (1.27-2.14)), men with baseline DM (HR = 1.78 (1.39-2.27)), and men with incident 
DM (HR = 2.15 (1.7-2.73), all of which they found to be oflower risk than participants 
with MI. [31] Of note, the authors mentioned that type 1 DM patients were excluded 
from the analysis but they did not mention by what grounds they excluded them. [31] 
A long term follow-up study (17-21 years) by Natarajan et al2005 [32] using the 
NHANES I cohort data did not differentiate between types of diabetes. It also divided it's 
participants into categories depending on length ofDM, recent diabetes (RDM) was 
considered <1 0 years and long term diabetes (LDM) > 10 years. They, like Hu et al. 
2005 [31], also noted that women that had LDM at baseline were at increased risk when 
compared to women with prior MI for CHD mortality, HR = 1.8 (1.1-3.2). [32] Unlike 
the women with long term diabetes, they found that women with a recent diagnosis of 
diabetes had an equivalent risk of CHD mortality compared to that of a woman with prior 
MI, HR = 0.9 (0.6-1.3). [32] They also found that both men with a recent diagnosis of 
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DM and those with a long term diagnosis ofDM had similar risks to patients with prior 
MI, HR 0.7 (0.3-1.3) and 0.8 (0.4-1.4), respectively. [32] 
As mentioned earlier, Haffner et al. 1998 [8] reported a HR of 1.2 (0.6-2.4) over 
an 8 year follow-up period when comparing people with prior MI to people with DM 
only. This HR represents an overall HR for the entire population of the study (including 
both men and women) due to the fact that Haffner did not divide the population into sub-
groups for analysis. However, Haffner [8] did an excellent job of excluding type 1 DM 
by measuring C-peptide levels, excluding patients diagnosed before age 30, and noting 
that none of the DM patients had a history of ketoacidosis. 
Juutilainen et al. 2005 [35], is the follow-up study to the original Haffner study 
[8]. The major improvements this study made over the older Haffner study [8] is that 
they continued to follow the original participants until a mean follow-up of 18 years, the 
results were reported by gender, and both the exposure and outcomes included separate 
results for other CVD. Despite the longer follow-up and the stratification of results they 
came to similar conclusions as the original Haffner study [8] with a HR for men with DM 
only compared to men with MI only of 0.85 (0.53-1.37) and an equivalent HR for women 
of 1.91 (0.6-6.08). [35] Although the risk comparison between MI and DM was 
statistically equivalent for women, it seems that it is likely that DM actually confers a 
higher risk for CHD mortality given the skewed CI and the robust HR.[35] 
Wannamethee et al. 2004 [30], using 10 year data on men from the British 
regional heart study, found that men with type 2 DM had equal risk to that of men with 
prior MI for future CHD mortality, HR for MI compared to DM = 1.47 (0.94-2.29). This 
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is in contrast to their finding, as mentioned above, within the same study that men with 
DM have a lower risk of CHD events than do their companions with only prior MI. 
Natarajan et al. 2003 followed men and women for 20 years that were members of 
the original Framingham Heart Study or members of the Framingham Offspring Study. 
[34) The authors found differing results on risk equivalency based on gender. Women 
with DM had similar risk for future CHD mortality than did women with prior MI, the 
HR for DM in reference to participants with neither condition is 3.6 (2.2-5.9) and the HR 
for prior MI compared to neither condition is 3.1 (1.2-7.6). Whereas men with DM had a 
lower risk for CHD mortality than did men with prior MI (HR for DM vs. neither= 1.7 
(1.2-2.5) and for prior MI vs. neither= 5.0 (3.6-6.9). [34) Note that this study is 
somewhat weak in that it uses two different populations (the different Framinghams) and 
two different CBG cutoffs for the definition of diabetes based on the population. Also, it 
did not mention the exact cutoff for diabetes in the Original Framingham Study, only that 
probable diabetes was two casual CBGs > 150 mg/dL or the use of hypoglycemic 
medicines. If this is the definition that was used then this is a very broad measure and 
will likely capture many "diabetics" that are at very low risk and may not even qualify for 
a true diagnosis of diabetes. 
Hu et al. 2001 [33) used 20 years of data over the years 1976-1996 from the 
Nurses Health Study (all women). They attempted to exclude type 1 diabetes by limiting 
their definition of diabetes to those diagnosed after age 30. They also stratified their 
outcomes by duration of disease, however they chose to separate the participants by 
doing one analysis with only baseline disease and then doing another analysis of baseline 
+incident cases. They found that the women that had DM at baseline had an equivalent 
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risk for CHD mortality as women with only prior MI by comparing the RRs of the two 
groups with reference to the group of women that had neither condition. The RR for 
women with DM was 7.48 (6.3-8.89), while the RR for women with MI was 8.15 (6.25-
10.6). [33] When assessing women with baseline disease in combination with incident 
disease, the risk of CHD death becomes lower for women with baseline or incident DM 
as it does for women with prior or incident MI (HR 5.65 (4.83-6.60) and 10.7 (9.03-12.6), 
respectively). [33] 
Cho et aL 2002 [36] is structured similarly to the Hu et aL 2001 study [33] with 
the major differences being that the Cho population consisted of males enrolled in the 
Health Professionals Follow-up study and the follow-up time was only over a period of 
10 years (between 1986 and 1996). Cho et aL [36]also attempted to exclude type I 
diabetes by excluding participants that self-reported to be type 1 and those that were 
diagnosed under the age of 30. In both subpopulations, men with baseline disease and 
men with baseline + incident disease, the risk for future CHD mortality was higher in 
men with MI only. In both cases when determining the HRs the exposed group was 
compared to the group that had neither condition, then the HRs for the exposed groups 
were compared to each other. For the men with baseline DM only the HR was 3.84 
(3.12-4.71) and the HR for men with prior MI only was 7.88 (6.86-9.05). [36] In this 
case the men with baseline+ incident DM had a HR of3.37 (2.72-4.17) as compared to 
the men with baseline MI, 8.39 (7.29-9.65). [36] 
Vaccaro et aL 2004 [37] followed men over a mean duration of25 years that were 
excluded from the MRFIT trial due to prior CHD or DM. They did not attempt to 
exclude patients with type 1 diabetes. In their population they found that DM was a lower 
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risk for CHD mortality than was prior MI, HR of prior MI in reference to prior DM was 
1.37 (1.26-1.48). [37] Of note, their definition ofDM did not include less severe diabetic 
patients due to the fact that they only included people that self-reported use of medication 
for diabetes. [37] However, it did include people with type I DM which may also bias 
the results, likely toward DM being a lesser risk factor than prior MI but not positively. 
Table 6. Risk for future CHD mortality comparing patients with prior DM only to those 
'th MI I WI 1pnor on y. 
The risk for future CHD deaths is higher in people with DM only as compared to those with only prior 
MI. 
Study (population) Risk measureinent [inverse] Definition of outcome 
Hu 2005 (women, baseline) [31] MI vs. DM: HR- 0.57 (0.39- ICD-9 codes 410-414 and 120-
0.82) [1.75 (1.22-2.56)] 25 
Natarajan 2005 (women, LDM) [32] DM vs. MI: HR- 1.8 (1.1-3.2) ICD-9 codes 410-414 
The risk for future CHD deaths is equivalent in people with DM only as compared to those with only 
prior MI. 
Study (population) Risk measurement [inverse] Definition of outcome 
Haffner 1998 (men and women) [8] DM vs. MI: HR- 1.2 (0.6-2.4) not explicitly stated, used 
WHO criteria to define Ml and 
searched hospital/autopsy 
records/death certificates 
Juutilainen 2005 (women) [35] DM vs. MI: HR ~ 1.91 (0.6- ICD-8 codes 410-414 
6.08) 
Juutilainen 2005 (men) [35) DM vs. MI: HR- 0.85 (0.53- ICD-8 codes 410-414 
1.37) 
Natarajan 2005 (women, RDM) [32] DM vs. MI: HR- 0.9 (0.6-1.3) ICD-9 codes 410-414 
Natarajan 2005 (men, RDM) [32) DM vs. MI: HR ~ 0. 7 (0.3-1.3) ICD-9 codes 410-414 
Natarajan 2005 (men, LDM) [32) DM vs. MI: HR ~ 0.8 (0.4-1.4) ICD-9 codes 410-414 
Wannamethee 2004 (men) [30] MI vs. DM: RR- 1.47 (0.94- ICD-9 codes 410-414 
2.29) [0.68 (0.44-1.06)] 
Natarajan 2003 (women) [34) DM vs. neither: HR ~ 3.6 (2.2- CHD~ MI/CI/AP. 
5.9) The outcome measured 
MI vs. neither: HR~ 3.1 (1.2- was CHD mortality (Obtained 
7.6) by a panel that reviewed 
records including a detailed 
history, clinical fmdings, EKG, 
autopsies, death certificates. 
Hu 2001 (women, baseline) [33] DM vs. neither: RR- 7.48 Hospital records or autopsy 
(6.30-8.89) listed CHD as cause of death-
MI vs. neither: RR~ 8.15 probable fatal CHD was when 
(6.25-10.6) CHD was coded on the death 
certificate but no records were 
available. Also included 
sudden deaths 
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The risk for future CHD death is lower in people with DM only as compared to those with only prior 
MI. 
Study (population) Risk measurement [inverse] Definition of outcome 
Hu 2005 (women, incident) [31] MI vs. DM: HR ~ 1.65 (1.27- ICD-9 codes 410-414 and I20-
2.14) f0.61 (0.47-0.79)] 25 
Hu 2005 (men, baseline)[31] MI vs. DM: HR- 1.78 (1.39- ICD-9 codes 410-414 and I20-
2.27) [0.56 (0.44-0.72)] 25 
Hu 2005 (men, incident)[31] MI vs. DM: HR ~ 2.15 (1.7- ICD-9 codes 410-414 and I20-
2.73) [0.46 (0.37-0.59)] 25 
Natarajan 2003 (men) DM vs. neither: HR- 1.7 (1.2- C~MIICI/AP. 
2.5) The outcome measured 
MI vs. neither: HR ~ 5.0 (3.6- was CHD mortality (Obtained 
6.9) by a panel that reviewed 
records including a detailed 
history, clinical findings, EKG, 
autopsies, death certificates. 
Hu 2001 (women, baseline + DM vs. neither: RR- 5.65 Hospital records or autopsy 
incident) [33] (4.83-6.60) listed CHD as cause of death -
MI vs. neither: RR ~ 10.7 probable fatal CHD was when 
(9.03-12.6) CHD was coded on the death 
certificate but no records were 
available. Also included 
sudden deaths 
Cho 2002 (men, baseline DM) [36] DM vs. neither: HR ~ 3.84 ICD-9 codes 410-414 
(3.12-4.71) 
MI vs. neither: HR ~ 7.88 
(6.86-9.05) 
Cho 2002 (men, baseline+ incident) DM vs. neither: HR- 3.37 ICD-9 codes 410-414 
[36] (2.72-4.17) 
MI vs. neither: HR ~ 8.39 
(7.29-9.65) 
Vaccaro 2004 (men) [37] MI vs. DM: HR- 1.37 (1.26- ICD-9-NACM codes 410-414, 
1.48) [0.73 (0.68-0.79)] 429.2 
Summary. Only one study [30] rated as fair addressed the risk comparison for future 
CHD events, finding that the risk for future CHD events is lower in people with DM 
compared to those with only prior MI (MI vs. DM RR = 1.59 (1.09-2.31 ). Thus, no 
concrete conclusions can be drawn regarding the comparative risk for future CHD events. 
Furthermore, the existing literature reflects differing outcomes to the question of whether 
all people with prior DM are at equivalent risk for future CHD mortality as are those with 
prior MI only. These studies were all rated as fair. Recurring themes contributing to fair 
ratings in this group of studies were lack of presentation of follow-up data, invalidated 
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measurement of disease exposures and confounding variables, and mediocre adjustment 
for confounding variables. 
Sub-question #1: Do patients with prior DM only have the same risk for future hard 
CHD events as those with other combinations of prior CVD (expanded exposure 
group)? 
Three studies not addressed above in the primary question [27-29] and three 
studies that addressed the primary question [30, 34, 35] reported outcome data comparing 
the risk of future hard CHD events in participants with prior DM only to those with a 
broader definition of prior CVD. The results for CHD mortality will be discussed in the 
context of the other studies. One of the new studies in this group, Eberly et a!. 2003 [28] 
received a rating of good for it's internal validity, while the others received a "fair" rating. 
These additional studies all had external validities that were fair-good. The results of 
these studies are summarized in tables 7 and 8, along with the definition of prior CVD to 
allow for appropriate analysis and the inverse of the RRIHR if the study reported in 
results as prior CVD in reference to DM. 
Studies that report effects when the outcome is def"rned as CHD events 
All of the studies with the exception ofWannamethee 2004 [30], who reported 
data on both CHD events and mortality, reported CHD mortality as the outcome. Using 
CHD events as the outcome, W annamethee et a!. calculated a RR of 0.92 (0.61-1.39) 
when comparing participants with angina pectoris in reference to participants with DM. 
[30] Thus, unlike their conclusion that DM is a lesser risk factor for future MI events 
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compared to prior MI, they found that when comparing people with DM to people with 
angina pectoris they are risk equivalents for future nonfatal MI. 
Table 7. Risk for future CHD events comparing patients with prior DM only to those 
with prior CVD only 
The risk for future CHD events is higher in people with DM only as compared to those with only 
other prior CVD. 
Study (population) Risk Measurement [inverse] Definition of prior CVD 
No studies Not applicable Not applicable 
The risk for future CHD events is equivalent in people with DM only as compared to those with only 
other prior CVD. 
Study (population) Risk Measurement [inverse] Definition of prior CVD 
Wannamethee 2004 (men) CVD vs. DM: RR~ 0.92 (0.61-1.39) Angina Pectoris only 
[30] [1.09 (0.72-1.64)] 
The risk for future CHD events is lower in people with DM only as compared to those with only other 
priorCVD. 
Study (population) Risk Measurement [inverse] Definition of prior CVD 
No studies Not applicable Not applicable 
Studies that report effects when the outcome is defmed as CHD mortality 
Whiteley et a!. 2005 [27] is one of the three studies that did not address our 
primary question but instead used a broader definition than only prior MI for the CVD 
exposure group. They compared the relative risk of CHD mortality of participants with 
prior DM only to that of participants with a history of a positive Rose questionnaire, 
severe chest pain lasting greater than 30 minutes, or EKG changes suggestive ofMI.[27] 
Their study was conducted in men and women ages 45-64 in two towns in Scotland.[27] 
They did not attempt to exclude type I DM but mentioned that it is highly likely that 
most had type 2 DM.[27] They found that women with DM were at a higher risk for 
future CHD mortality than are women with CHD, relative risk for people with DM vs. 
CHD = !.97 (!.27-3.08).[27] However for men they found that DM conveyed a similar 
risk for CHD mortality as does prior CHD, relative risk for people with DM vs. CHD = 
!.17 (0.78-!.74). 
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Eberly et a!. 2003 [28] is another one of the three studies that used an expanded 
definition of prior CVD to determine CHD mortality risk. In this case they defined CVD 
as reporting a history of coronary bypass surgery, a history of non-fatal stroke, a history 
of non-fatal MI, or a history of silent MI by EKG before the last annual visit of the cohort 
study.[28] Of note, all of these men would have been excluded at the beginning of the 
RCT, thus all of the participants in the cohort study have a relatively short duration of 
disease.[28] This holds true for the population with DM as well.[28] They did not 
attempt to exclude participants with type 1 DM, however given that all of the cases were 
diagnosed in adulthood it is likely that the vast majority of the participants with DM have 
type 2 DM. Eberly et al. [28] conducted their analysis on a post-randomized controlled 
trial (RCT) cohort from the years 1982-1999. The cohort that they used was the MRFIT 
cohort, a group of men at increased risk for CHD aged 35-57 at baseline that were 
selected to participate in a RCT addressing the primary prevention of CHD mortality. 
Note, all of the men enrolled in the study were willing to make major life changes in 
order to improve their cardiovascular health (such as quit smoking, diet, and go to annual 
medical visits). [28] This limits the external validity of the study to fair when compared 
to the average American patient. Overall, they found that men with DM have a lower 
risk for CHD mortality as compared to men with prior CVD, hazard ratio for men with 
non-fatal CVD in reference to men with DM = 1.88 (1.51-2.34).[28] 
The last study to use an expanded exposure group for the CVD group is Lotufo et 
al. 2001.[29] Lotufo et al. 2001 [29] defined prior CHD as self-report of history ofMI or 
angina pectoris. They studied the U.S. Physician's Health Study cohort which only 
included males ages 40-84 at baseline (1983).[29] They did not directly exclude type 1 
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DM but mentioned that given the age distribution of the population that it was likely that 
the majority had type 2 DM.[29] All men with a history of cancer, stroke, liver disease or 
renal disease were excluded, which somewhat limits the external validity of this study, 
thus it was also only given a fair. They found that the risk of CHD mortality was lower 
in the people with DM (RR compared to those without DM or CHD = 2.9 (2.3-3.7) when 
compared to those with prior MIIAP (RR compared to those without DMIMI = 5.4 (4.7-
6.2).[29] 
Juutilainen et a!. 2005 [35], in addition to examining the relative risk of CHD 
mortality of having DM compared to having MI, did further analysis based on different 
definitions of CHD. They defined CHD in three other ways besides only hospital 
verified MI: 1) angina pectoris only (Rose criteria) 2) EKG changes only and 3) MI, AP, 
or EKG changes.[35] As a reminder, they found that both men and women with diabetes 
were are equivalent risk for CHD mortality in reference to men and women with prior MI 
only (DM vs. MI: HR for men= 0.85 (0.53-1.37), HR for women= 1.91 (0.6-6.08).[35] 
When comparing the risk for CHD mortality in men with DM to men with expanded 
CHD exposure definitions Juutilainen et a!. [3 5] found that when compared to men with 
either EKG changes only or to the group of men with MI,AP, or EKG changes, men with 
DM have a mildly higher risk for future CHD mortality (HR DM vs. EKG changes= 
1.54(1.02-2.33), HR DM vs. MIIAP/EKG changes= 1.50(1.01-2.22).[35] They found a 
slightly different answer when comparing men with DM to men with prior AP only found 
that they have an equivalent risk of CHD mortality (HR DM vs. AP only= 1.45(0.9-
2.34).[35] For all categories of CHD exposure (except prior MI only), they found that 
women with DM have a higher risk for CHD mortality than do women with prior 
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CHD.[35] The hazard ratios are as follows: 1) DM vs. AP only= 4.86(2.08-11.33) 2) 
DM vs. EKG changes only= 4.27(2.08-8.79) and 3) DM vs. MIIAP/EKG changes= 
3.52(1.83-6.79).[35] 
Wannamethee et al2004 [30] found that when changing their definition ofCHD 
from prior MI only prior angina pectoris men with diabetes continued to be at equivalent 
risk for CHD mortality as those with CHD, HR AP onlyvs. DM = 0.79 (0.48-1.30).[30] 
However, the risk ofDM for CHD mortality was somewhat stronger in reference to AP 
when compared to the risk ofDM for CHD mortality in reference to prior MI, HR MI vs. 
DM = 1.47(0.94-2.29). 
Natarajan eta!. 2003 [34] also examined the risk for CHD mortality in women 
with DM compared to that of women with angina pectoris/coronary insufficiency 
(AP/CI). As a reminder, they found that women with DM were at an equivalent risk for 
CHD mortality as were those with prior MI only (HR DM vs. neither= 3.6(2.2-5.9), HR 
MI vs. neither= 3.1 (1.2-7 .6)).[34] When comparing the risk of CHD mortality in women 
with DM to women with AP/CI they also found risk equivalence, albeit just barely (HR 
AP/CI vs. neither= 1.5(0.9-2.7), HR DM vs. neither= 3.6(2.2-5.9)).[34] Looking at the 
95% confidence intervals of the above HRs it is likely that DM actually imparts a higher 
risk for CHD mortality than does AP /CL 
Table 8. Risk for future CHD mortality comparing patients with prior DM only to those 
with prior CVD only 
The risk for future CHD deaths is higher in people with DM only as compared to those with only 
other prior CVD. 
Study (population) Risk Measurement [inverse] Definition of prior CVD 
Whiteley 2005 (women) [27] DM vs. CVD: HR ~ 1.97 Positive Rose questionnaire, 
(1.27-3.08) severe chest pain> 30 min, EKG 
changes 
Juutilainen 2005 (men) [35] DM vs. CVD: HR- !.54 EKG changes 
(1.02-2.33) 
Juutilainen 2005 (men) [35] DM vs. CVD: HR ~ 1.50 Ml, AP, or EKG changes 
(1.0 1-2.22) 
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Juutilainen 2005 (women) [35] DM vs. CVD: HR- 4.86 AP 
(2.08-11.33) 
Juutilainen 2005 (women) [35] DMvs. CVD: HR-4.27 EKG changes 
(2.08- 8.79) 
Juutilainen 2005 (women) [35] DM vs. CVD: HR ~ 3.52 MI, AP, or EKG changes 
(1.83-6.79) 
The risk for future CHD deaths is equivalent in people with DM only as compared to those with only 
other prior CVD. 
Study (population) Risk Measurement [inverse] Definition of prior CVD 
Whiteley 2005 (men) [27] DM vs. CVD: HR- 1.17 (0.78- Positive Rose questionnaire, 
1.74) severe chest pain >30 min, EKG 
changes 
Juutilainen 2005 (men) [35] DM vs. CVD: HR ~ 1.45 (0.9- AP 
2.34) 
Wanoamethee 2004 (men) [30] CVDvs. DM: RR- 0.79 (0.48- Angina ouly 
1.30) [1.27 (0.77-2.08)] 
Natarajan 2003 (women) [34] DM vs. neither: HR- 3.6 (2.2- Angina pectoris 
5.9) Coronary Insufficiency 
CVD vs. neither: HR ~ 1.5 (0.9-
2.7) 
The risk for future CHD deaths is lower In people with DM only as compared to those with only 
other prior CVD. 
Study (population) Risk Measurement [inverse] Definition of prior CVD 
Eberly 2003 (men) [28] Nonfatal-CVD vs. DM: HR- 1.88 Coronary Bypass surgery 
(1.51-2.34) [0.53 (0.43-0.66)] Non fatal stroke 
NonfatalMI 
silent Ml 
Lotufo 200 I (men) [29] DM vs. neither: RR- 2.9 (2.3-3.7) MI 
CVD vs. neither: RR~ 5.4 (4.7-6.2) Angina 
Summary. Not surprisingly, when expanding the CHD exposure group to include less 
severe cardiovascular diseases than MI (such asAP, EKG changes, CI, severe chest pain 
>30 min, positive Rose questionnaire) the hazard ratios for CHD mortality comparing 
people with DM to people with CVD lean toward assigning more risk to DM than prior 
CVD.[27, 30, 34, 35] This was true even when a statistically significant change in risk 
equivalency compared to a more narrow definition of CHD, only MI, was not seen.[30, 
34] Also Eberly et al. 2003 [28] expanded their definition to include other severe 
markers of CVD (coronary bypass surgery, nonfatal stroke, nonfatal MI, and silent MI on 
EKG) and found that having DM was a lesser risk factor for CHD mortality when 
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compared to having prior CVD. Lotufo et aL 2001 [29] is unique in that they included 
AP in their definition of prior CHD yet still found a lower relative risk for CHD mortality 
in people with DM than people with prior CHD.[29] Unfortunately, they did not do an 
analysis looking only at prior MI as the definition of CHD for comparison. Given what 
we have just learned, it is likely that the relative risk for CHD mortality in participants 
with DM would be even lower when compared to participants with prior MI only. 
Sub-question #2: Do patients with prior DM only have the same risk for future hard 
CVD events as those with prior Mlonly (expanded outcome measure)? 
Using data from the studies that addressed our primary question and data from 
other studies that we identified through our literature search we will attempt to draw 
some conclusions about this sub-question. Note however, that we did not do a separate 
full systematic review on this topic and that it is likely that our search terms missed some 
studies that would be pertinent to this topic. Results can be found in Tables 9 and 10, 
along with a definition of the outcome measured and the inverse of the risk measurement 
if it was calculated in the study as MI in reference to DM. 
Studies that report effects when the outcomes is def"med as CVD events 
Two studies [30, 38] examined the risk for future CVD events in people with DM 
only compared to people with CHD only, see Table 9. Both of these studies found that 
having DM leads to an equivalent risk for future CVD events as does having prior MI 
only. Wannarnethee et aL [30] and Lee et aL [38] both defined CVD events as "major 
stroke events" including fatal and nonfatal outcomes. Lee et aL did not make this 
comparison looking at the outcome ofCHD events. Wannarnethee et aL [30] did 
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examine CHD event outcomes, in contrast to CVD event outcomes they found people 
with DM to be at lower risk for CHD events than people with prior MI only. 
Table 9. Risk for future CVD events in people with DM only as compared to those with 
prior MI only 
The risk for future CVD events is higher in people with DM only as compared to those with only 
J>.rior MI. 
Study (population) Risk measurement [inverse] Definition of outcome 
No studies Not applicable Not applicable 
The risk for future CVD events is equivalent in people with DM only as compared to those with only 
prior MI. 
Study (population) Risk measurement [inverse] Definition of outcome 
Wannamethee 2004 (men)[30] MI vs. DM: RR~ 0.87 (0.51-1.49) Stroke that produced a 
[1.15 (0.67-1.96)] neurological deficit that 
was present >24 hours. 
Lee et al2004 (men and women)[38] Mlvs. DM: RR- 1.05 (0.61-1.79) defutite or probable 
[0.95 (0.56-1.64)] hospitalized embolic, 
hemorrhagic, or 
thrombotic stroke 
The risk for future CVD events is lower in people with DM only as compared to those with only prior 
MI. 
Study (population) Risk measurement [inverse] Definition of outcome 
No studies Not applicable Not applicable 
Studies that report effects when the outcomes is def"med as CVD mortality 
Seven of the studies addressing the primary question[30, 31, 33, 35-38] also 
examined CVD mortality as an outcome. Within the seven studies there were 13 
subpopulations that were examined, see Table 10 for a summary of their results. It is also 
helpful to refer to Table 6 for comparisons with the outcome of CHD mortality. 
Hu et al2005 [31] in their subpopulation of women with baseline DM was the 
only group whereby having DM conferred a significantly higher risk for future CVD 
mortality than did MI, HR for MI. vs. DM = 0.63(0.47-0.84).[31] This finding is 
consistent with their earlier finding that having DM confers a higher risk for CHD 
mortality than does prior MI.[31] Their findings for women comparing incident DM and 
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MI for CVD mortality were slightly different than their findings for CHD mortality. For 
CVD mortality they found that having incident DM was of equivalent risk as having 
incident MI, HR for MI vs. DM = 1.22(0.98-1.53).[31) Whereas for CHD mortality the 
analogous HR was 1.65(1.27-2.14).[31) Comparing both outcomes (CHD mortality and 
CVD mortality) in men they found that, in both subpopulations looking at both outcomes, 
having DM conferred a lower risk for mortality than did MI. The hazard ratios 
comparing those with MI only to those with DM only in men were; baseline/CHD 
mortality 1. 78(1.30-2.27), baseline/CVD mortality 1.43(1.6-1. 77), incident/CHD 
mortality 2.15(1.7-2.73), incident/CVD mortality 1.41(1.16-1.71). 
Juutilainen et a!. 2005[35) found that in both men and women having DM confers 
a statistically equivalent risk for CVD mortality as does having prior MI, HRs DM only 
vs. MI only are 1.00(0.64-1.58) and 2.89(0.92-9.11) respectively.[35) However, it seems 
that when assessing women in this study the risk for CVD mortality is likely higher for 
DM than MI due to the skewing of the confidence interval and the robust HR.[35) 
Juutilainen et a!. found similar results when the outcome was CHD mortality, for both 
men and women that DM confers a statistically equivalent risk for CHD mortality when 
compared to prior Ml, HRs DM only vs. MI only are 0.85(0.53-1.37) and 1.91(0.6-6.08) 
respectively.[35) Once again, although not statistically significant the risk for women 
from DM for CHD mortality is likely higher than from MI given the skewing of the Cl 
and the robust HR.[35) 
Wanamethee et a!. 2004 [30) in their study of men also found that the risks 
conferred by DM and prior MI are equivalent for both CHD mortality and CVD 
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mortality.[30] The relative risk for MI only vs. DM only for CHD mortality was 
1.47(0.94-2.29), whereas for CVD mortality it was 1.42(0.98-2.05).[30] 
Hu eta!. 2001 [33] also came to similar conclusions about risk equivalency when 
comparing CHD and CVD mortality risk in participants with DM only and those with MI 
only. They found that women with baseline DM are risk equivalents to women with 
baseline MI for CVD mortality, RR ofDM vs. neither= 6.59(5.69-7.63) vs. RR ofMI vs. 
neither= 6.58(5.19-8.36).[33] The equivalent relative risks when looking at CHD 
mortality are 7.48(6.30-8.89) and 8.15(6.25-10.6), respectively.[33] This finding is also 
interesting in that it allows for comparison of risk between CHD mortality and CVD 
mortality. In this case the risks conferred by baseline MI or baseline DM are similar 
regardless of the outcomes measured. When Hu eta!. [33] examined the risks for 
mortality in the group of women with baseline or incident DM only or baseline or 
incident MI only, they found that when looking at either CHD or CVD mortality that 
people with DM are at lower risk than are people with MI.[33] The relative risk ofCVD 
mortality in women with baseline or incident DM only compared to a person with neither 
MI or DM was 4.86(4.27-5.52), the equivalent RR for women with baseline or incident 
MI only was 7.46(6.43-8.66).[33] Analogous RR for an outcome ofCHD morality were 
5.65(4.83-6.60) and 10.7(9.03-12.6), respectively.[33] 
Cho eta!. 2002 [36] had the same subpopulation divisions as Hu eta!. 2001 [33] 
with the exception that their study was conducted in men. In both subpopulations of men, 
they found that for CVD mortality the hazard ratio for men with diabetes only was lower 
than that of men with MI only.[36] For men with baseline only disease the hazard ratio 
for CVD mortality in men with DM in reference to men without DM/MI was 3.34(2.80-
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3.99) compared to the hazard ratio for men with MI in reference to men without DMIMI 
that was 5.63(4.97-6.39).[36] The analogous hazard ratios for CHD mortality in men 
with baseline disease were 3.84(3.12-4.71) and 7.88(6.86-9.05). For men with baseline 
or incident disease the hazard ratio for CVD mortality in men with DM in reference to 
men without DMIMI was 2.75(2.29-3.30) compared to the hazard ratio for men with MI 
in reference to men without DM/MI that was 5.51(4.88-6.23).[36] For men with baseline 
or incident disease the analogous hazard ratios for CHD mortality were 3.3 7 (2. 72-4.17) 
and 8.39(7.29-9.65).[36] Thus, the conclusions for CVD mortality are the same in all of 
their subpopulations as were their conclusions for CHD mortality.[36] 
Vaccaro et a!. 2004 [37] did not find a change in risk equivalency between DM 
and MI when comparing the outcomes of CHD mortality and CVD mortality. In their 
study of men they calculated a hazard ratio for CVD mortality in men with prior MI only 
in reference to men with prior DM only of 1.25(1.16-1.34).[37] Their hazard ratio 
comparing the same groups for the outcome of CHD mortality was 1.37(1.26-1.48).[37] 
Interestingly they did find that when only measuring risk of death from stroke, having 
diabetes conferred a higher risk for mortality than did prior MI, HR stroke vs. DM = 
0.61 (0.46-0.80).[37] 
Lee et a!. 2004 [38] found that having MI confers a greater risk for CVD mortality 
than does having DM, RR MI vs. DM = 1.82(1.22-2.72). This finding is similar to their 
finding that people with prior MI only have a greater risk of hard CHD events (including 
CHD mortality) than do people with DM, RR MI vs. DM = 1.86(1.35-2.56).[38] This 
difference in CVD mortality risk was noted despite their finding that DM and MI confer 
equivalent risks for overall number of CVD events, RR = 1.05(0.61-1.79). [38] 
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Table 10. Risk for future CVD death in people with DM only as compared to those with 
prior MI only 
The risk for future CVD deaths is higher in people with DM only as compared to those with only prior 
CHD. 
Study (population) Risk measurement [inverse] Definition of outcome 
Hu 2005 (women, baseline) [31) M1 vs. DM: HR ~ 0.63 (0.47- 1CD-9 codes 390-459 and IOO-
0.84) [1.59 (1.19-2.13)) 199 
The risk for future CVD deaths is equivalent in people with DM only as compared to those with only 
prior CHD. 
Study (population) Risk measurement Definition of outcome 
Hu 2005 (women, incident dm) [31) MI vs. DM: HR ~ 1.22 (0.98- 1CD-9 codes 390-459 and IOO-
1.53) [0.81 (0.65-1.02)) !99 
Juutilainen 2005 (women) [35] DM vs. MI: HR ~ 2.89 (0.92- ICD-8 codes 390-459 
9.11) 
Juutilainen 2005 (men) [35] DM vs. Ml: HR- 1.00 (0.64- ICD-8 codes 390-459 
1.58) 
Wannamethee 2004 (men) [30] M1 vs. DM: RR ~ 1.42 (0.98- ICD-9 codes 410-439. 
2.05) [0.70 (0.49-1.02)] 
Hu 2001 (women, baseline dm) [33] DM vs. neither: RR ~ 6.59 ICD-9 codes 390-459 and 795 
(5.69-7.63) 
MI vs. neither: RR ~ 6.58 
(5.19-8.36) 
The risk for future CVD death is lower in people with DM only as compared to those with only prior 
CHD. 
Study (population) Risk measurement [inverse] Definition of outcome 
Hu 2005 (men, baseline dm)[31] Ml vs. DM: HR~ 1.43 (1.16- ICD-9 codes 390-459 and 
1.77) [0.70 (0.56-0.86)] I00-!99 
Hu 2005 (men, incident dm)[31] Ml vs. DM: HR- 1.41 (1.16- ICD-9 codes 390-459 and 
1.71) [0.71 (0.58-0.86)] I00-199 
Hu 2001 (women, baseline+ incident DM vs. neither: RR ~ 4.86 ICD-9 codes 390-459 and 
dm) [33] (4.27-5.52) 795 
Ml vs. neither: RR ~ 7.46 
(6.43-8.66) 
Cho 2002 (men, baseline + incident dm) DM vs. neither: HR- 2.75 ICD-9 codes 390-459 and 
[36] (2.29-3.30) 795 
Ml vs. neither: HR ~ 5.51 
( 4.88-6.23) 
Cho 2002 (men, baseline dm) [36] DM vs. neither: HR- 3.34 ICD-9 codes 390-459 and 
(2.80-3.99) 795 
M1 vs. neither: HR ~ 5.63 
(4.97-6.39) 
Vaccaro 2004 (men) [37] Ml vs. DM: HR~ 1.25 (1.16- ICD-9-NACM codes 390-
1.34), [0.8 (0.75-0.86)] 459 
stroke only 0.61 (0.46-0.80) 
[1.64 (1.25-2.17)] 
Lee et al2004 [38] MI vs. DM: RR- 1.82 (1.22- death certificate I CD-9 
2.72) [0.55 (0.37-0.82)] codes 390-459 
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Summary. In almost all cases there was no change in risk equivalency ofDM only and 
MI only when comparing the outcomes of CVD and CHD mortality. Thus, the results for 
CVD mortality based on the presence ofDM or MI were found have heterogeneous 
outcomes as did the results for CHD mortality. One study [3 7] reported results for only 
fatal stroke events, finding that participants with DM have a higher risk than do 
participants with prior MI. Both studies addressing CVD events (defined as nonfatal and 
fatal stroke) found risk equivalency between DM and MI.[30, 38] Since there are few 
studies, a definitive conclusion regarding CVD events cannot be made. 
Sub-question #3: Does having other markers of CVD in patients with prior DM 
change the risk for future hard CHD events when they are compared to those with 
prior MI only? 
Only one of our included studies, Wannamethee eta!. [30], measured other types 
of CVD in the participant subgroups. They found that within the diabetic population 
5.9% recalled having a stroke, 6.4% reported chest pain on exertion, 3.5% reported 
severe chest pain (used as a marker for possible MI), and 19.3% reported breathlessness. 
[30] However, they did not stratify the results comparing those with DM that had these 
symptoms to those with DM that did not have these symptoms so they were not able to 
further compare those risk measurements to the risk found in participants with only prior 
MI. 
Summary. From the data we assembled, no conclusions can be drawn regarding the 
question of whether the presence of markers of other CVD events in the diabetic 
population changes the risk comparison with that of participants with prior MI only. 
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Sub-question #4: Does the answer to the question of whether patients with prior DM 
only have the same risk for future hard CHD events as those with prior MI only 
change based on the risk stratification of the groups (high vs. low risk)? 
Four of the studies addressing our primary question [33, 36, 37] or an extension of 
our primary question [29] included data comparing the risk of future CHD mortality 
based on other CVD risk factors. Hu 2001 [33], Cho 2002 [36], and Lotufo 2001 [29] 
calculated RRs based on individual CVD risk factors, see Table II. Vaccaro eta!. [37] 
stratified their outcome data based on the number of other CVD risk factors among 
smoking status, SBP < 130 vs. SBP 2': 130 mmHg, or serum cholesterol < 200 vs. 2':200 
mg/dL. Of note, in Vaccaro et al.'s [37] comparison both the patients with diabetes and 
the patients with MI had the stated number of risk factors (0-3), see Table 12. 
Hu eta!. 2001 [33] calculated the relative risk of CHD mortality modified by 
CVD risk factors in female participants that had either baseline or incident DM or MI. 
As a reminder, for this population Hu eta!. found that participants with DM have a lower 
risk of CHD mortality than do participants with MI (RR: DM vs. neither= 5.65( 4.83-
6.60), MI vs. neither= 10.7(9.03-12.6). [33] In all cases the relative risks for the 
subgroup analysis were in reference to the group of participants that was free of the risk 
factor in question, DM, and MI. They found that the risk for CHD mortality was 
significantly higher in participants with DM with hypertension than in participants with 
DM and no hypertension, RR = 13.3(10.9-16.2) vs. 5.51(3.97-7.63) respectively.[33] In 
fact, the participant with DM and hypertension had a RR for CHD mortality similar to 
that of participants with prior MI and no hypertension, RR = 13.3(1 0.9-16.2) vs. 
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15.3(11.6-20.2) respectively.[33] For high cholesterol and family history ofMI the 
relative risks for participants with DM with the risk factor were higher than that of 
participants with DM without the risk factor but the differences were not significant. [33] 
Also in both cases, participants with MI regardless of the presence of the risk factor in 
question had a significantly higher risk for future CHD death. [33] One limitation of this 
analysis is that Hu et al. 2001 [33] did not state their definitions of hypertension or high 
cholesterol, thus the reader is left to assume that they used a valid measure. 
Cho et al. 2002 [36] in their study of male health professionals also used their 
baseline+ incident population to do subgroup analyses for CHD mortality risk by risk 
factors. However, they chose to use a referent group specific for the presence or absence 
of the risk factor. For example: the relative risk of CHD mortality in participants with 
hypertension and DM or MI was calculated in reference to a population with 
hypertension that does not have DM or MI. This is in contrast to a the relative risk of 
CHD mortality in participants without hypertension but with DM or MI that was 
calculated in reference to a population without hypertension, DM, or MI. The decision to 
use different referent groups is somewhat limiting due to the fact that the two subgroups 
of participants with DM or MI (those with the exposure of interest (DM or MI) and the 
risk factor and those with said exposure but without the risk factor) cannot be compared 
to one another. The conclusion that we can derive is that, with the exception of a positive 
history of parental MI, the risk for future CHD mortality is significantly lower in 
participants with DM when compared to participants with MI when participants in both 
groups are compared to each other by presence of absence of hypertension, high 
cholesterol, and parental history of MI. [36] Those participants with DM and a positive 
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family history ofMI had a lower relative risk ofCHD mortality (RR = 4.14 (2.38-7.23) 
than did participants with MI and a positive family history ofMI (RR = 8.20 (5.82-11.57), 
but this result was not significant.[36] This study is limited in the same way as the Hu et 
a!. 2001 [33] study, in that Cho eta!. 2002 [36] did not state their definition of 
hypertension or high cholesterol. 
Lotufo et a!. 2001 [29], in their study of male physicians, addressed multiple 
subgroup analyses specific for risk factors. These include hypertension, high cholesterol, 
body mass index (BMI), smoking status, exercise level, and alcohol intake. [29] Of note 
this is the study that defined their CHD exposure group as people with prior MI or prior 
angina pectoris so the results are not perfectly comparable to the other three studies 
addressing this sub-question which all used prior MI as their measure of CHD. They, 
like Hu et al2001 [33], used the same reference group, those free of the risk factor, DM, 
and MI, for all populations of interest when calculating their relative risks for a particular 
risk factor. For reference, they found that the overall relative risk for CHD mortality is 
lower in people with DM as compared to those with only prior MI/AP (RR: DM vs. 
neither= 2.9(2.3-3.7), MI/AP vs. neither= 5.4(4.7-6.2).[29] For these analyses they 
defined hypertension as SBP2160, DBP295, or use of anti-hypertensive medication.[29] 
Their definition of high cholesterol was a total cholesterol of2260 or the use of anti-
cholesterol medication.[29] Lotufo et al. [29] found that participants with diabetes 
stratified by hypertensive status had a non-significant difference in risk for CHD 
mortality, although the relative risk for those with diabetes and hypertension was higher 
than for those with diabetes but without hypertension (RR = 5.0 (3.6-6.9), 3.5 (2.5-4.9), 
respectively).[29] The risk for participants with DM and HTN was lower but not 
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significantly different than the risk for participants with Mil AP without HTN (RR = 
5.0(3.6-6.9), 6.9(5.7-8.2), respectively).[29] The analysis for high cholesterol is 
especially interesting in that people with DM and high cholesterol had a lower relative 
risk, RR = 1.8 (0.8-4.0) for future CHD mortality than did people with DM without high 
cholesterol, RR = 3.0(2.3-3.9).[29] This finding, while not of statistical significance and 
thus could be due to chance, is interesting because one would expect that participants 
with more risk factors for CHD would be at higher risk of CHD mortality. One 
hypothesis is that since Lotufo et a!. [29] included patients that were treated with 
cholesterol lowering medications when defining high cholesterol, it may be the beneficial 
effects oflowering cholesterol that are responsible for the lower relative risk in the 
patients with both DM and high cholesterol. Lotufo et a!. [29] found that BMI is not 
significantly correlated with risk of CHD mortality in either people with DM or people 
with Ml!AP, however there seems to be a trend toward worse CHD outcomes as BMI 
increases in participants with DM.[29] Looking at Lotufo et al.'s [29] data, men with 
prior CHD that currently smoke have a significantly high relative risk, RR = 13.6(1 0.1-
18.2), for CHD mortality in comparison to the relative risks of men with DM in any 
smoking category and men with CHD that were either past smokers or never 
smokers.[29] When assessing the relative risk of CHD mortality with reference to 
amount of vigorous exercise, while it is not statistically significant, there seems to be a 
trend that within disease exposure category (DM or CHD) that those participants that 
exercised more than 1/week had lower relative risks for CHD mortality.[29] Furthermore, 
the relative risk for patients with DM that exercise <!/week, RR = 4.5(3.3-6.2), is not 
significantly different than the relative risk for patients with CHD that exercise ~1/week, 
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RR = 5.7(4.8-6.8).[29] Among all divisions within a disease exposure group, the relative 
risks for CHD mortality based on alcohol intake (recorded as daily, weekly, or ~onthly) 
were not significantly different but trended upward with less frequent alcohol use. Also, 
people with diabetes that consumed alcohol daily had a significantly lower relative risk 
for CHD mortality, RR= 2.0(1.1-3.5), than did any of the participants with CHD 
regardless of alcohol status.[29] 
Vaccaro eta!. 2004 [37] combined risk factors (SBP::::l30, cigarette smoking, total 
cholesterol ::::200) into a composite score (0-3) which they used to calculate a hazard ratio 
comparing men with prior MI to men with prior DM based on the number of risk factors 
present. When an hazard ratio was generated for the population without regards to 
subpopulations, they found that men with DM were at lower risk for CHD mortality than 
are men with prior MI, RR (MI in reference to DM) = 1.37 (1.26-1.48).[37] This 
conclusion held true for all categories of risk factors (0-3) when calculating relative risks 
stratified by number of risk factors.[3 7] 
Table 11. RRs for CHD death for patients with DM or CHD based on individual CVD 
risk factors * 
Hypertension 
Study (population) RR CHD mortality Referent Definition of risk 
RF? DM CHD group factor 
Hu et al. 2001 Yes 13.3(1 0.9-16.2) 23.0(18.5-28.7) noHTN,no not mentioned 
(women, baseline+ No 5.51(3.97-7.63) 15.3(11.6-20.2) CHD,no 
incident) f33l DM, 
Cho et al. 2002 (men, Yes 2.36(1.81-3.07) 5.76(4.79-6.91) HTN,no not mentioned 
baseline+ incident) DM,no 
[36] CHD 
No 4.13(2.86-5.96) 11.84(9 .55-14.67) noHTN, 
noDM,no 
CHD, 
Lotufo et al. 200 I Yes 5.0(3.6-6.9) 9.3(7.6-11.2) noHTN,no SBP<:!60,DBP2:95, 
(men) [29] No 3.5(2.5-4.9) 6.9(5.7-8.2) CHD,no or anti-HTN med 
DM 
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High Cholesterol 
Study (population) RR CHD mortality Referent group Definition of 
RF? DM CHD risk factor 
Hu eta!. 2001 Yes 7.09(5.71- 12.1(9.65- no high cholesterol, not mentioned 
(women, baseline+ 8.81) 15.1) noDM,noCHD 
incident) [33] No 5.68(4.51- 11.8(9.30-
6.99) 14.9) 
Cho et a!. 2002 (men Yes 2.79(1.97- 6.71(5.43- high cholesterol, not mentioned 
baseline+ iocident) 3.96) 8.29) noDM,noCHD 
[36] No 3.59(2.73- 9.03(7.45- no high 
4.71) 10.94) cholesterol, no 
DM,noCHD 
Lotufo eta!. 2001 Yes 1.8(0.8-4.0) 6.6(5.2-8.4) no high cholesterol, TC;:>:260 
(men) [29] No 3.0(2.3-3.9) 5.3(4.5-6.1) noDM,noCHD mg/dL or anti-
Cholesterol 
med 
Family History of MI 
Study (population) RR CHD mortality Referent group Definition of 
RF? DM CHD risk factor. 
Hu eta!. 2001 (women Yes 8.22(6.14- 16.1(12.3- no family Hx,no parental MI 
baselioe + incident) 11.0) 21.0) DM,noCHD before age 60 
[33] No 5.86(4.92- 11.1(9.05-
6.98) 13.5) 
Cho eta!. 2002 (men Yes 4.14(2.38- 8.20(5.82- Hx parental Ml, no parental MI 
baselioe + iocident) 7.23) 11.57) DM,noCHD before age 60 
[36] No 3.24(2.56- 8.51(7.30- no Hx parental MI, 
4.09) 9.92) noDM,noCHD 
BMI 
Study (population) RR CHD mortality Referent group Definition of 
RF? DM CHD risk factor 
Lotufo eta!. 2001 <22 2.4(1.1-5.0) 6.0(4.3-8.4) BMI<22,no kg/m2 
(men) [29] 22-24 2.9(1.9-4.6) 5.4(4.1-7.2) DM,noCHD 
25-29.9 2.9(1.9-4.4) 5.4(4.0-7.2) 
2:30 5.4(3.1-9.5) 7.1(4.4-11.3) 
Smoking Status 
Study (population) RR CHD mortality Referent group Definition of 
RF? DM CHD risk factor 
Lotufo eta!. 2001 never 3.2(2.2-4.7) 6.2(4.9-7.8) never never, past, 
(men) [29] past 3.8(2.7-5.4) 6.0( 4.9-7 .4) smoking, no current 
current 4.7(2.6-8.4) 13.6(10.1-18.2) DM,noCHD 
Vigorous Exercise 
Study (population) RR CHD mortality Referent group Definition of 
RF? DM CHD risk factor 
Lotufo et a!. 2001 ;:>:!/week 2.8(2.0-4.0) 5.7(4.8-6.8) :2::1/week, no rarely/never, 
(men) [29] <!/week 4.5(3.3-6.2) 7.9(6.5-9.5) DM,noCHD 1-3/month, 
1-4/week, 
<:5/week 
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Alcohol Intake 
Study {population) RR CHD mortality Referent group Definition of 
RF? DM CHD risk factor 
Lotufo et al. 2001 daily 2.0(1.1-3.5) 5.8(4.5-7.4) daily, no DM, never, 
(men) [29] weekly 3.3(2.2-5.0) 6.2( 4.9-7 .8) noCHD rarely, 
:<;monthly 4.7(3.4-6.6) 7.2(5.7-9.1) monthly, 
weekly, 
daily 
' *Lotufo s pnor CHD group mcludes those w1th pnor MI or AP. Hu and Cho ouly mclude pnor/mc1dent MI. 
Table 12. Hazard Ratio of CHD mortality in patients with MI compared to patients with 
DM based on composite# of other risk factors * 
Vaccaro et al. [37] (men) 
Number of risk factors HR (MI vs. DM) 
in patients with MIIDM 
0 1.49 (1.06-2.10) 
I 1.32 (1.14-1.52) 
2 1.32 (1.18-1.49) 
3 1.32 (1.08-1.61) 
*other nsk factors mclude c1garette smoking, SBP ~ 130 mmHg, or serum cholesterol ~200 mg/dL 
Summary. It is difficult to make definitive conclusions regarding risk factors and CHD 
mortality because it is hard to compare the studies due to different populations, 
measurements of risk factors, and measurements of exposure. Two of the studies allowed 
comparisons between DM subgroups (those with the risk factor and those without) and 
comparisons between DM and MI groups based on risk factors.[29, 33] While the two 
other studies only allowed comparisons between participants with DM and participants 
with MI based on the presence or absence of certain risk factors.[36, 37] Given the cases 
that reached statistical significance and the trend patterns, it seems likely that people with 
DM have differing levels of risk of CHD mortality based on the presence or absence of 
CVD risk factors. In some cases, when referenced to people with CHD that did not have 
risk factors, the presence of risk factors in the population with DM caused a statistically 
significant change in the risk equivalency generated for the primary question. This was 
not true when comparing the risk of CHD mortality of people with DM and people with 
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MI that had the same risk factors, or same number of risk factors. In all four of the 
studies the overall relationship of the relative risks for CHD mortality between having 
DM or MI did not change when stratified by risk factor (although in a few cases the 
outcome lost significance likely due to inadequate power). This is most clearly seen 
when looking at the scheme that Vaccaro et al.[37] presented their results. 
Sub-questions #5-#8: Does the answer to the question of whether patients with prior 
DM only have the same risk for future hard CHD events as those with prior MI only 
change based on the demographic characteristics ofthe study group (gender, age, 
duration of disease, and time period of the study)? 
#5 Gender. All but two of the studies addressing the overall question had outcome data 
that were gender specific. [30-37]In addressing this sub-question we will refer to Table 6 
since the data are already separated by gender. 
The only studies that reported a finding where people with diabetes had a risk of 
CHD death greater than that of a person with prior MI reported this finding within a 
female population that had diabetes for what they classified as a longer duration (defined 
as diabetes> I 0 years in one study, and as baseline data in the other) [31, 32]. Within 
those same studies the other sub-populations of people with DM or MI were not found to 
be of such high risk. 
Furthermore, in all 6 subpopulations of studies that had both male and female 
comparison groups (Hu 2005 baseline, Hu 2005 incident, Natarajan 2005 long duration, 
Natarajan 2005 short duration, Juutilainen 2005, and Natarajan 2003) the HR comparing 
the risk for future CHD mortality in participants with DM in reference to participants 
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with prior MI only was higher for the female subpopulation as compared to the HR for an 
equivalent male subpopulation. [31, 32, 34, 35] This difference was significant in 1 ofthe 
subpopulations, Hu 2005 baseline [31]. 
Summary. Although there seems to be a trend toward diabetes in women being a higher 
risk factor for CHD mortality when compared to prior MI than in men, gender does not 
completely explain the heterogeneous findings to our primary question because the 
difference in risk equivalency is not neatly drawn between gender lines. There are 
studies of men that show equivalency and there are studies that show that men with 
diabetes are at less risk than men with prior MI. Likewise, there are subpopulations of 
women within every risk comparison category. 
#6 Age. Four studies that were included in the evidence table for the primary question, 
[33, 35-37] and one study [29] that was included in the expanded exposure sub-question 
table reported sub-group analyses of age. A summary table of their findings can be found 
in Table 13. 
Overall only two studies showed a significant change in risk equivalency based on 
age range, Lotufo et al. 2001 [29] and Hu et al. 2001 [33]. 
Lotufo et al. [29] failed to show significantly different relative risks between 
people with prior DM and people with prior Mil angina for future CHD events in the age 
range of 40-54 DM. Whereas they significantly showed that at age 55 or above DM 
confers a lower risk of future CHD deaths than does MI. However, given the wide 
confidence intervals and the large gap between the numerical HRs, it is likely that had the 
study been well powered it would have also shown that people with diabetes in the 40-54 
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year-old age range are also at lower risk for future CHD events when compared to people 
with prior MI. 
Hu et al. [33] found that women with baseline or incident DM only that are less 
than 65 years of age have a significantly lower relative risk of CHD mortality than do 
women with a history of baseline or incident MI. However, they noted that women with 
diabetes who are greater than or equal to the age of 65 may have an equivalent relative 
risk of future CHD mortality as to women with MI. Power is somewhat limited for this 
last measurement as evidenced by wide confidence intervals, it is likely that if the study 
had enough events in the <:65 age range the difference in relative risks would have 
continued to be significant. Perhaps more importantly, when looking at the risk 
difference between MI and DM over the different age categories it becomes obvious that 
as the women in the study aged the risk difference became closer, suggesting that as 
women age DM plays more of a part in risk when compared to MI. 
All but one of the other studies only examined men. They all found that the 
relative difference between MI and DM were similar as the participants aged. 
Table 13. Relative risk ofCHD mortality in people with DM compared to people with MI 
stratified by age 
Hu et al. 2001 [331 subgroup: women, baseline +follow-up incident cases 
Age Range RR compared to < 55 with neither condition Relative Difference (MI!DM) 
<55 years DM = 9.19 (6.39-13.2), Ml = 29.2 (19.7-43.3) 3.18 (1.49-6.78) 
55-64 years DM- 21.5 (16.4-28.3), MI- 44.4 (33.3-58.9) 2.07 (1.18-3.59) 
;:, 65 years DM = 42.7 (31.4-58.1), Ml = 66.3 (47.8-92.0) 1.55 (0.82-2.93) 
Juutilainen et al. 2005 135] subgroup: baseline onlv 
Age Range HR comparing DM no MI to Ml no DM 
Age< median (<56.9) all- 0.96 (0.47-1.96), men- 0.86 (0.39-1.89), women- 1.67 (0.21-13.24) 
Age> median (;:,56.9) all= 1.00 (0.57-1.72), men= 0.81 (0.43-1.52), women= 2.14 (0.52-8.85) 
I Lotufo et al. 2001 [29] subgroup: men, baseline only I 
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Age Range RR comparing to same age range with neither Relative Difference (CHD/DM) 
condition 
40-54 DM ~ 7.4 (3.8-14.5), MI/AP ~ 14.1 (9.3-21.3) 1.91 (0.64-5.61) 
55-69 DM ~ 3.1 (2.3-4.4), MIIAP ~ 6.1 (5.0-7.3) 1.97 (1.14-3.17) 
70-84 DM- 1.9 (1.3-2.8), MIIAP- 3.6 (2.9-4.4) 1.89 (1.04-3.38) 
Vaccaro et al. 2004 [37] subgroup: men, baseline only 
Age Range HR comparing MI only vs. DM only 
35-39 1.89 (1.22-2.92) 
40-44 1.94 (1.5-2.52) 
45-49 1.59 (1.33-1.91) 
50-54 1.21 (1.07-1.38) 
55-57 1.22 (1.03-1.44) 
Cho et a!. 2002 [36] sub~ roup: men, baseline +follow-up incident cases 
Age Range RR compared to same age range with neither Relative Difference 
condition (MIIDM) 
<60 DM ~ 6.16(3.37-11.28), MI ~ 18.37(12.36-27.36) 2.98 (1.10-8.12) 
60-69 DM- 3.50 (2.45-4.99), MI- 9.52 (7.56-11.99) 2.72 (1.52-4.89) 
?::70 DM ~ 2.68 (1.99-3.61), MI ~ 6.26 (5.19-7.56) 2.34 (1.44-3.80) 
Summary. Given the above data, it is unlikely that age is a major contributor to the 
variation seen in the outcomes of our primary question for men. However it may play a 
larger part in women, that is as women age the rate at which DM is risk for CHD 
morality increases faster than does the rate for MI, leading to closer risk equivalency 
between the two. 
#7 Glycemic Load. None of our studies examined the effects ofHbAlC levels or other 
indicators of glycemic control, thus in order to examine the effects of overall glycemic 
load on risk of future CHD events we will use only duration of disease. 
Eight studies [28, 30-33, 35-37], through various methods, allow for comparison 
of duration of diabetes and/or MI on CHD risk equivalency. Refer to table 14 for a 
summary of the results. 
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Hu et aL 2001 [33] found that, in women, the risk of future CHD mortality 
increased significantly and steadily with the increase in duration of diabetes. The RRs of 
fatal CHD compared with non-diabetic women without CHD across the diabetes duration 
ranges of :0: 5years, 6-10 years, 11-15 years,> 15 years were 1.0, 3.07, 4.24, 7.59, and 
8.66(6.87-10.9), respectively.[33] They did not report a P-value for trend. In the same 
model they reported that the RR for CHD mortality for women with vs. women without 
CHD was 8.61(7.08-10.5), suggesting that women with DM only are at similar risk for 
CHD mortality than are those with prior CHD only. [33] Hu et aL [33] reinforced this 
concept by dividing their participants into subpopulations ofbaseline disease vs. baseline 
+incident disease. In this case the group with baseline disease has a higher RR for DM 
vs. neither (7.48 (6.30-8.89))and a lower ratio for MI (8.15 (6.25-10.6)) vs. neither when 
compared to baseline+ incident disease (5.65 (4.83-6.60) and 10.7 (9.03-12.6), 
respectively). 
Cho et aL 2002 [36] conducted a similar analysis in their study of men that also 
noted an increase in risk of future CHD mortality with increasing duration of diabetes. 
Their multivariate adjusted RRs for death from CHD compared to participants without 
DM or CHD according to duration of diabetes in people without CHD were 1.0, 2.0, 3.0, 
3.7, 4.4, and 7.5 for:<;; 5 years, 6-10 years, 11-15 years, 16-25 years, and;:: 26 years, 
respectively (no P values or Cis reported). [36] In this model the RR for CHD mortality 
in men with CHD vs. men without DM or CHD was 8.3.[36] Cho et aL [36] also divided 
their population into subgroups, those with baseline + incident disease and those with 
baseline disease. While in both cases the participants with DM were at lower risk for 
future CHD death, the HRs continue to affirm the findings that DM is more of a risk later 
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in the disease course while MI is more of a risk early in its course. This is seen by noting 
that the HR for baseline DM only is higher than baseline+ incident DM (3.84 (3.12-4.71) 
and 3.37 (2.72-4.17), respectively), while this is reversed for MI (7.88 (6.86-9.05) and 
8.39 (7.29-9.65), respectively). [36] 
Wannamethee eta!. 2004 [30] stratified their analysis by duration of diabetes in a 
similar fashion to that ofHu et al2001 [33] and Cho eta!. 2002 [36], but they did not 
divide their population into duration groups as did Hu eta!. [33] and Cho eta!. [36]. 
Their multivariate adjusted RRs in reference to participants without diabetes or CHD, for 
death from CHD according to duration of diabetes were 2.16 (1.17-3.97), 3.23 (1.33-
7.88), and 4.04 (2.86-7.93) for diabetes duration of< 7 years, 7-12 years, and> 12 years, 
respectively (P<O.OOl for trend).[30] For comparison they found the relative risk for 
CHD mortality in men with doctor diagnosed MI when compared to participants without 
diabetes or CHD was 3.91 (3.07-4.99), while for all participants with diabetes the RR was 
2.82 (1.85-4.28).[30] Wannamethee, once again, was the only study to examine the 
outcome of CHD events. When considering CHD events, their multivariate adjusted RRs 
in reference to participants without diabetes or CHD were 1.67 (1.01-2.75), 2.65 (1.31-
5.35), and 2.67 (1.46-4.88) for diabetes duration of< 7 years, 7-12 years, and> 12 years, 
respectively (P<0.001 for trend).[30] This measurement for participants with prior MI 
only was 3.16 (2.59-3.86) and for all participants with DM was 2.09 (1.48-2.96).[30] 
Juutilainen eta!. 2005 [35] stratified their hazard ratios for death from CHD 
events into diabetes duration below the mean ( < 8 years) and diabetes duration above the 
mean (2 8 years). For diabetes duration below the mean the HRs comparing diabetic 
subjects without prior MI with nondiabetic subjects with prior MI for all comers, women, 
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and men were 1.0 (0.63-1.60), 0.96 (0.56-1.63), and 1.78 (0.53-5.94), respectfully.[35] 
For those with diabetes duration above the mean the HRs were 0.91 (0.58-1.43), 0.71 
(0.42-1.19), and 2.06 (0.64-6.66), respectfully.[35] 
Vaccaro eta!. 2004 [37] used follow-up period as a surrogate marker of duration 
of disease. They compared the HR for CHD deaths between prior MI only in reference to 
prior diabetes. For a follow-up periods of::; 5 years, 6-10 years, 11-15 years, 16-20 years, 
and >20 years the HRs were respectively 2.71 (2.14-3.43), 1.74 (1.46-2.08), 1.20 (1.02-
1.42), 1.05 (0.87-1.26), and 1.00 (0.83-1.20). Although we do not know the exact 
duration of disease, we do know that as the follow-up time increases the time from 
exposure to either DM or MI also increases equally, thus we are able to draw some 
conclusions. As time elapses when comparing the risk of CHD death of prior DM to 
prior MI the HR trends toward increasing risk from DM when compared to MI. 
Hu eta!. 2005 [31] divided their participants into subpopulations of baseline 
disease vs. incident disease. This division inherently divides the population into older 
duration of disease (baseline groups) and newer duration of disease (incident groups) 
allowing for comparisons to be made between the two. In women the HR for CHD 
mortality of the baseline study was 0.57 (0.39-0.82) when comparing those with prior MI 
in reference to those with DM. [31] Compared to the HR for the female incident group, 
1.65 (1.27-2.14), the risk from diabetes compared to prior MI is much higher in the 
baseline group. [31] In fact, diabetes in the baseline group confers a significantly higher 
risk for future CHD mortality, whereas in the incident group it confers a significantly 
lower risk than prior MI. This suggests that as time passes after the event diabetes 
assumes more of a risk for future CHD mortality than does prior MI. 
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Natarajan eta!. 2005 [32] also divided their population into subgroups, however 
they choose to divide them based on recent diagnosis ofDM (less than 10 years) vs.long 
term diagnosis of DM (at least 1 0 years). They found that women with long term 
diabetes have a risk of CHD mortality that is higher than women with prior MI, HR 1.8 
(1.1-3.2). [32] This is in contrast to their finding that women with recent diabetes were at 
a risk equivalent to those with prior MI for CHD mortality, HR 0.9 (0.6-1.3). [32] They 
found similar results for men with recent diabetes as compared to long term diabetes, 
HRs 0.7 (0.3-1.3) and 0.8 (0.4-1.4) respectively. 
Since we know that all of the participants in the Eberly et al2003 [28] cohort 
were diagnosed with either DM or CVD (defined as coronary bypass surgery, nonfatal 
stroke, nonfatal MI, silent MI) within the six years leading up to the study we can gain 
some insight into duration of disease, rather it be DM or CVD, and its relative impact on 
CHD mortality. In this case, men with diabetes had a lower risk for future CHD events 
with compared to men with prior, hazard ratio of nonfatal-CVD in reference to men with 
DM = 1.88 (1.51-2.34).[28] 
Table 14. Assessing the impact of duration ofDM on CHD mortality in patients with 
DMb t .th t . CHD U WI ou:pnor 
Hu et al. 2001 [33] 
Duration ofDM RR DM* only vs. no DM/MI RR prior Ml only vs. no DM/MI 
noDM 1.0 8.61 (7.08-10.5) 
<5 years 3.07 
6-10 years 4.24 
11-15 years 7.59 
> 15 years 8.66 (6.87-10.9) 
I Overall outcomes based on the two subJJ<lllulations 
Group DM vs. no DMIMI Ml vs. no DMIMI 
Baseline RR ~ 7.48(6.30-8.89) RR ~ 8.15(6.25-10.6) 
Baseline + incident RR ~ 5.65(4.83-6.60) RR~ 10.7(9.03-12.6) 
*did not report P value for trend, no specific individual Cis stated unless listed. 
I Cho et al. 2002 [36] I 
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Duration ofDM RR DM* only vs. no DM/CHD RR prior MI only vs. no DM/CHD 
noDM 1.0 8.3 
<5 years 2.0 
6-10 years 3.0 
11-15 years 3.7 
16-25 years 4.4 
> 26 years 7.5 
Overall outcomes based on the two subpopnlations 
Group DM vs. no DM!MI MI vs. no DM!MI 
Baseline RR = 3.84(3.12-4.71) RR = 7.88(6.86-9.05) 
Baseline + incident RR- 3.37(2.72-4.17) RR- 8.39(7.29-9.65) 
*did not report P value for trend or specific individual Cis 
Wannamethee eta!. 2004[30] 
Duration ofDM RR CHD deaths (DM vs. no DM/CHD) T RR CHD events (DM vs. no 
DM/CHD)t 
<?years 2.16(1.17-3.97) 1.67(1.0 1-2.75) 
7-12 years 3.23(1.33-7.88) 2.65(1.31-5.35) 
>12 years 4.04(2.86-7.93) 2.67(1.46-4.88) 
Overall outcomes in reference to people without DM or CHD 
RR CHD deaths RR CHD events 
DM 2.82(1.85-4.28) 2.09(1.48-2.96) 
MI 3.91(3.07-4.99) 3.16(2.59-3.86) 
t P value for trend P<O.OOl 
Juutilainen eta!. 2005[35] 
Results presented as HRs comparing DM no MI in reference to MI no DM 
Group All subjects Men Women 
Diabetes duration <8yr 1.00(0.63-1.60) 0.96(0.56-1.63) 1.78(0.53-5.94) 
Diabetes duration>8yr 0.91(0.58-1.43) 0.71 (0.42-1.19) 2.06(0.64-6.66) 
Vaccaro eta!. 2004[37] 
Results presented as HR for CHD mortality, MI no DM in reference to DM no MI 
Period of Follow-up HR 
<5 years 2.71(2.14-3.43) 
6-10 years I. 74(1.46-2.08) 
11-15 years 1.20(1.02-1.42) 
16-20 years 1.05(0.87-1.26) 
> 20 years 1.00(0.83-1.20) 
Hu eta!. 2005[31] 
Results presented as HR for CHD mortality comparing MI no DM in reference to DM no MI 
Group Men Women 
Baseline DM vs. MI 1.78(1.39-2.27) 0.57(0.39-0.82) 
Incident DM vs. MI 2.15(1.7-2.73) 1.65(1.27-2.14) 
Natarajan eta!. 2005[32] 
Results presented as HR for fatal CHD, DM no MI vs. MI no DM 
Group I Men I Women 
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I RecentDM (<!Oyrs) I 0.7(0.3-1.3) .I o.9(o.6-1.3J I I Long term DM (>!Oyrs) I o.8(o.4-L4l 1 !.8(1.1-3.2) I 
Eberly et al. 2003[28) 
Hazard ratio for CHD deaths in people with Nonfatal CVD only in reference to those with DM only 
Participants diagnosed in previous 6 years~ 1.88(1.51-2.34) 
Summary. Overall, although the results areu't completely in agreement, it does seem to 
be plausible that the answer to our primary question could differ based on duration of 
diabetes. This may especially be true when analyzing the comparative risk between DM 
and MI of duration from exposure of the event (either DM or MI). There are some 
suggestions from the data that MI assumes more of a risk early on and that diabetes 
assumes more of a risk later in the course of the disease. [31, 33, 36] This was further 
demonstrated in a population of men where the CHD exposure group was expanded to 
include men with coronary bypass surgery, nonfatal stroke, nonfatal MI, or silent MI.[28] 
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Discussion 
What we found 
Primary Question. We identified 1 0 studies of adequate internal and external validity 
that addressed our primary question. From those studies we identified 19 sub-population 
comparison groups for CHD mortality and 1 for nonfatal CHD events. We found that: 
CHD events 
• there are not enough studies to determine whether or not DM is a CHD risk 
equivalent to prior MI for future CHD events. The one study that we identified 
found that prior MI conferred a higher risk than DM for future nonfatal MI. 
CHD mortality 
• there are mixed effects when assessing whether or not DM is a cardiovascular risk 
equivalent to prior MI for CHD mortality. 
• due to heterogeneity in study results comparing the risk of CHD mortality in 
people with DM to people with prior MI, there is high uncertainty that their risks 
are universally equivalent. 
• it is likely that these mixed effects are due to risk factor and demographic 
differences in the populations assessed (see sub-questions). 
Sub-question #1: Expanded CHD exposure group. Of the studies that addressed our 
primary question, we identified three studies (8 comparison groups) with CHD mortality 
as the outcome that also addressed Sub-question #I: Do patients with prior DM only have 
the same risk for future hard CHD events as those with other combinations of prior CVD 
(expanded exposure group). One of those studies [30) also reported outcome measures 
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for future nonfatal CHD events. We also identified three other studies ( 4 comparison 
groups) addressing this question from our literature search. We found that: 
CHD events 
• there are not enough studies to determine whether or not DM is a cardiovascular 
risk equivalent to prior MI for future CHD events. The one study we identified 
found that DM and prior angina pectoris are risk equivalents for future nonfatal 
MI. 
CHD mortality 
• there is little uncertainty that when the definition of CHD is expanded to include 
less severe cardiovascular disease (AP, CI, EKG changes alone), the relative risk 
(or hazard ratio) for CHD mortality is increased when comparing people with DM 
in reference to people with CHD. This was not always statistically significant). 
• there is minimal evidence to show what happens to the relative risk (hazard ratio) 
of CHD mortality comparing DM to CVD when the definition of CHD exposure 
is expanded to include other more severe cardiovascular diseases (CABO, stroke, 
nonfatal MI). Eberly eta!. 2003 [28] expanded their prior CHD definition to 
include other severe markers of CVD and found that having DM was a lesser risk 
factor for CHD mortality when compared to having prior CVD. They did not 
assess the risk equivalency of only MI to serve as a comparison. 
• One study, by Lotufo eta!. 2001 [29], expanded the CHD definition to include 
self-report ofMI and AP and found that people with self-report ofDM were at 
lower risk of CHD mortality than people with prior CHD. However they did not 
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do an analysis with only DM as the definition of CHD to allow adequate 
comparisons to be made. 
Sub-question # 2: Expanded Outcomes. Seven of the 10 studies addressing our 
primary question also reported outcomes for hard CVD events (non-fatal CVD, CVD 
mortality (including CHD mortality)). We found that: 
CVD events 
• there is minimal research to determine whether or not DM is a cardiovascular risk 
equivalent to prior MI for future CVD events. Both studies identified defined 
future CVD events as stroke and suggested that prior DM and prior MI are risk 
equivalents for future CVD events. 
CVD mortality 
• due to heterogeneity in study results comparing the risk of CVD mortality in 
people with DM to people with prior MI, there is high uncertainty that their risks 
are universally equivalent. Most studies suggest that prior MI confers a higher 
risk for CVD mortality than prior DM. 
• there is little uncertainty that within a study the risk equivalence between MI and 
DM that is calculated for CVD mortality will be the same as the risk equivalence 
calculated for CHD mortality. 
Sub-question# 3: Other CVD in DM group. We only identified one study [30] that 
measured other markers of CVD or CVD events in the diabetic population. This study 
did not make any conclusions regarding the level of risk people with diabetes and 
markers of CVD have when compared to people with diabetes that do not have markers 
of CVD or people with prior MI only. We found that: 
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• there is inadequate research to determine if the presence of other markers of CVD 
in people with diabetes changes the risk of future CHD events in relation to 
diabetics that do not have other markers of CVD or people with prior MI. 
Sub-question #4: High vs. Low risk. We identified 4 studies that compared different 
CVD risk levels in patients with DM or MI in relation to the outcome of CHD mortality. 
We found that: 
• Risk factors do not appear to change conclusions about risk equivalency. There is 
some uncertainty mainly due to lack of a significant number of studies that 
compare the same risk factors and present their results in comparable ways. 
• In most cases the presence of CVD risk factors increases the likelihood outcomes 
for both prior DM and prior MI. The exceptions are in the Hu eta!. 2001 
[33]study for women with DM and high cholesterol and for BMI in the CHD 
population in the Lotufo eta!. 2001 [29]study. 
• In some cases, comparing participants with DM and risk factors to participants 
with CHD but no risk factors changed the equivalency level that was determined 
by the primary question. 
Sub-question #5: Gender. We identified 8 studies [30-37] addressing the primary 
question that reported results specific to gender. We found that: 
• there is little uncertainty that gender changes the risk equivalency, with DM 
conferring a greater risk for CHD mortality than prior MI in females when 
compared to males (and vice versa). 
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Sub-question #6: Age. We identified four studies addressing the primary question [33, 
35-37] and one study [29] with an expanded exposure group that stratified results 
dependent on age. We found that: 
• there is little uncertainty that age does not significantly changes the risk 
equivalency between DM and CHD in men. There is some uncertainty that age 
changes the risk equivalency between DM and CHD in women. 
• It appears that as women age there is less differential in risk between those with 
prior DM and those with prior CHD. 
Sub-question #7: Glycemic Load. We identified 7 studies [30-33, 35-37] that examined 
the effect of duration of diabetes and/or MI on CHD risk equivalency. We found that: 
• no studies examined the effect of glycemic control on the comparable CHD risk 
ofDM vs. prior MI. 
• there is some uncertainty that the duration of diabetes changes the risk 
equivalency levels for future CHD mortality when comparing people with DM to 
people with prior MI. 
• there is little uncertainty that the duration of diabetes changes the risk equivalency 
levels for future CHD mortality in people with DM vs. prior MI when also taking 
into account duration of MI. MI seems to confer a higher risk early on, while DM 
assumes a higher risk later. 
Problems with the literature 
The literature is limited by the necessity to use cohort studies, which inevitably 
contain confounding factors that cannot be controlled for and that can cause a study to 
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arrive at a biased conclusion. Thus it is absolutely imperative that cohort studies 
adequately adjust for possible confounding factors. All of the studies that were excluded 
from our review were excluded due to lack of proper statistical adjustment for potential 
confounders. Furthermore, many of the studies that were included in our review were 
held from receiving a "good" rating for internal validity due to shortcomings in 
adjustment for confounders. Thus, we do not have any "good" quality cohort studies on 
which to base our conclusion about our primary question. 
Overall the external validity of the results was fair. One area of weakness is that 
there is not very much data on minority patients that a typical American physician can 
expect to treat. Also, many of the included studies were done in populations that had 
better access to medical services than a typical American, rather it be an American 
member of the health care system or a Brit with access to the NHS. Despite these 
shortcomings we were able to identifY many American population based studies for the 
review. [27, 31, 34, 37, 38] 
Perhaps the major limitation of the literature for determining the risk for future 
CVD/CHD events ofDM as compared to MI is that there is not a standardized way of 
determining and measuring exposures and outcomes. This is a very complex issue thus 
there are many studies that ask the same question, "Is DM a CVD risk equivalent", but 
attempt to answer it via different exposure groups and by measuring different outcomes. 
This makes it somewhat difficult to make comparisons between studies. Overall, this 
may lead to generalizations that may not be accurate. 
Limitations of this review 
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One limitation of this review is that there is a high chance that we missed relevant 
studies because we were only able to search one database, MEDLINE, and we were 
unable to find unpublished studies. We attempted to capture as many studies with 
MEDLINE as possible, using the option "clinical queries" so that Cochrane was 
encompassed. Thus, we feel that the only major database we missed was EMBASE. We 
only had two primary reviewers to extract and appraise the data. Furthermore, while both 
of the primary reviews have had standardized training in critical appraisal of medical 
literature, neither are experts. We attempted to minimize this deficit by involving a third 
expert reader to assist with mentoring of the process and adjudication of disagreements. 
Furthermore, although we attempted to involve experts in the field on as many of the 
steps as possible, the primary authors are not experts on diabetes or cardiovascular 
disease. 
Implications of this review 
Clinical Practice. Given the heterogeneity in outcomes for the primary question, this 
review suggests that physicians should not treat all diabetics as CHD risk equivalents 
when determining LDL targets and LDL cut-offlevels for treatment with statins. 
Furthermore, we have shown that level of risk for future CHD mortality changes within 
the DM population when assessing individual risk factors (sub-question #4) and that there 
is reason to believe that risk level changes based on demographic factors (sub-questions 
#5-7). This suggests that in the lower risk populations, those with short duration of 
disease and few other risk factors, it is imperative for the clinician to calculate the 
absolute risk of future CHD events on an individual basis before universally treating 
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patients with DM based on the NCEP guidelines. This is especially true when treating a 
patient with type 1 diabetes, until further data on this disease is known, where the 
recommendations were made based on studies of patients with type 2 diabetes, a disease 
with different pathophysiology and different risk factor clustering. All medications, 
including statins, have unwanted side effects causing harm for patients, thus care should 
be taken when making blanket statements for treatment. Statins have been shown to be 
capable oflowering CHD risk in patients with type II diabetes without overt CHD but 
with at least one other risk factor [39], they should be used when a clinician considers the 
absolute risk of a patient with diabetes, based on their individual risk factors and their 
potential benefit to harm ratio, to be of an adequate level to treat. 
Research. We have shown that multiple large, long duration, cohort studies of adequate 
quality and generalizabilty have addressed the question of whether or not diabetes is a 
risk equivalent for CHD mortality when compared to prior MI and have yet to reach 
consensus. Thus, it is unlikely that more studies such as these that continue to group all 
diabetics together will reach a consensus on whether diabetes itself is a CHD risk 
equivalent for future hard CHD events. Focus of the research should be turned instead to 
the nuances of diabetes as a CHD risk factor. One measurement that is vital to answering 
the question of whether DM is a CHD risk equivalent but was near universally absent 
from the studies in this review is "When was DM or prior CHD diagnosed?" a measure of 
how long has the participant has had the exposure. Attention should be given to 
addressing what other factors, as well as how many/what combinations of risk factors 
make a diabetic person of significantly high risk to treat with statins at the cutoffs set for 
people with cardiovascular disease. This can be best achieved through large cohort 
66 
studies that, a priori, do multiple grouped stratification divisions of their population 
analysis based on demographics and risk factors. For instance to aid in sorting out the 
effects of gender and duration it would be helpful to design a study with population 
stratification such as young/female/short duration vs. old/female/long duration vs. 
young/male/short duration, etc. Also, a systematic review similar to this one should be 
done for a population with type 1 diabetes to see where their coronary heart disease risk 
falls. Given that the pathophysiology of the two different types of diabetes is entirely 
different, type I diabetes warrants future research because it is unlikely that they have 
equal risks for CVD as do patients with type 2 diabetes. 
Final Conclusion 
The NCEP ATP III guidelines recommend to treat the cholesterol level in all 
patients with diabetes as if they have prior CHD. [4] However, comparing the risk for 
future CHD events in people with DM to those with prior MI is more complex than it 
seemed at the time these recommendations were given. The heterogeneity in results of 
the studies that we identified suggests that not all patients with diabetes are at an equally 
high level of CHD risk. This was further supported by showing, through sub-group 
analysis, that not all diabetics are at the same risk when stratifying by demographics and 
other CHD risk factors. Additionally, many of the broad groups of patients addressed in 
our primary question with diabetes were at lower risk of CHD mortality than were 
patients with MI. Therefore, it is unwise to universally treat all people with diabetes as 
CHD risk equivalents. Some high risk populations, those with many other CVD risk 
factors, prior CHD and long duration of disease should still be treated as risk equivalents, 
67 
this is especially true for women. However, it is more prudent in some low-risk 
populations, such as young people with short duration of disease, those with few other 
risk factors and those without evidence of other CVD, to calculate their absolute risk for 
future CHD events and treat based on the individual rather than the presence of diabetes. 
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Appendix A: Critical Appraisal Tables 
Population and Selection Bias Table 
Source, Population/ How Duration of Potential for 
Years of it Was Obtained Group Number of Age #ffype of RFs Sex Prior prior Loss to F/U Selection Bias and 
study Participants CVD disease (MI Rating 
or dm) 
Hu, et al. Married DMno 3,705 (in 1986) mean ~1 1986 100%F No data no data on estimated Rating- II 
2001.[1] Registered Nurses Ml 63.1 Smokev2l.O mean that follow-
inll most HTN- 55.9 duration, up for Both groups from 
1976-1996 populous state[2] Chol- 28.2 outcome was same source 
Parental Hx MI <60y- 24.1 >98% population 
had data for 20 Sent out baseline Insulin- 25.8 complete 
years of questionnaire, Oral med- 32.4 Selection bias 
follow-up 121,700 of BMI- 29.8 inherent to cohot1 
170,000 Post-Men Honnone- 17.1 study, but well 
responded[2] Exercise - 2.8 hr/week adjusted in this study. 
EtOH- 3.0gld 
final population ""' Mlno 1302 (in 1986) mean In 1986 IOO%F No data N/A estimated Not sure how 
l2!,046 DM 65.1 Smoke-27.1 that follow- estimated LTF or if it 
Baseline= 69. HTN- 47.7 up for was differential but 
attempted to Chol- 32.9 outcome was since only 2% likely 
exclude type 1 dm Parental Hx MI<60y - 31.1 >98% low. 
BMI- 26.7 complete 
Post-Men Honnone- 19.4 
Exercise - 2.8 Risk Factor Data 
hr/wk taken at the median 
EtOH- 6.0gld point of the study. 
Booth et al. Residents 2::: 20 DM no no data no data 110 data no data 110 data no data, no data Rating - fatal flaw 
2006[3] years old in the Ml 
registered persons Mlno no data no data no data no data no data N/A no data Really don't know 
April 1 1994- database of DM anything about the 
March 31, Ontario who were two groups of interest 
2000 eligible for (even though they 
coverage under the drew conclusions 
Ontario Health between the 2) 
ll1surm1ce Plan 
Don't know anything 
did not tly to about follow-up 
exclude Tvoe I 
Cho eta!. Health DMno Baseline Mean In 1986 100% no data no data on Overall94% Rating- II 
2002[4] Professionals MI 1,285 61 Smoke- 10% M mean for each 2 
Follow-up Study. HTN -44% duration year cycle Both groups from 
1986- January (dentists, Updated= 2, Chol- 24% same source 
31, 1996 veterinarians 428 Parental Hx MI <60y - attempted to not sure what population 
phannacists, 14% exclude type percentage 
10 year optometrists, ODs, Insulin - 19% I. of outcome Selection bias 
follow-up and podiatrists) Oral med- 31% data was inherent to cohort 
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40-75 years of age mean BMI -26 obtained. study, but well 
at baseline. mean Exercise - 16 adjusted in this study. 
86% employed hr/week 
96%white mean EtOH- 8 g/d Concemed about 
Mlno Baseline Mean~ hl 1986 100% no data NIA Overall94% LTF. Not sure how 
final population = DM 2,038 63 Smoke- 13% M for each 2 many did not have 
51,316 HTN- 38% year cycle info on death or if it 
Updated= 3, Chol-41% was differential. 
attempted to 652 Parental Hx Ml <60y - not sure what 
exclude type 1. 30% percentage 
mean BMI- 26 of outcome 
mean Exercise - 18 data was 
hr/week obtained 
mean EtOH- llg/d 
Eberly, et a!. 11,645 men ages DMno 1,122 RCT Baseline: 100% no data fasting follow-up Rating ll 
2003 [5] 35-57 years at NF-CVD Baselin Smoke- 62% M glucose at was> 90% 
baseline RCT trial 9% African eMean Fasting total cholesterol - baseline of at each of Choosing was very 
RCTphase who survived the 6 America ~47.1 238.4 RCTwas trial visits good - both groups 
1976-1982 year RCT and did Parental Hx of heart 106.1 mg/dl. subject to same 
not have dm and disease - 60% criteria and chosen 
Post Trial were at increased EtOH drinks/week- 12.8 All cases from same 
Cohort follow- risk but without diagnosed population. 
up28 definitive clinical During RCT Averaged: after 1982. 
February evidence ofCHD. Systolic BP- 129.3 Differences inherent 
1982-31 HDL-39.2 to cohort study well 
December Rec1uited at 22 LDL- 144.9 adjusted. 
1999 clinical centers in BM1-29.2 
the US.[6] Thiazide use- 72% Not sure about 
Median P-blocker use- 29% percentage of 
follow-up was Initial RCT outcome 
18.5y selected people End ofRCT: Smoke- 34% measurements 
that were at high NF-CVD 658 RCT Baseline: 100% no data mean fasting follow-up obtained and if the 
modifiable risk of noDM Baselin Smoke- 73% M glucose at was> 90% loss was differential 
CVD and willing 4% African eMean Fasting total cholesterol- baseline of at each of or not. 
to make changes American ~ 47.3 249.2 RCT~96.5 trial visits 
in theirCVD Parental Hx of heart 
status ( eg. quitting disease - 69% 
smoking, diet EtOH drinks/week- 11.9 
change)[6] 
During RCT Averaged: 
Systolic BP -125.7 
HDL-40.2 
LDL-161.5 
BM1- 27.1 
Thiazide use - 59% 
P-blocker use - 41% 
End of RCT: Smoke- 43% 
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Evans, Wang, Patients, aged 45- dmnoMI Baseline ("cross Baselin no data Baselin no data Baseline no data Rating: fatal flaw 
andMon·is 64, in Tayside sectional emean e~ mean 
2002. [7] Scotland who study"): 1,155 of 57 42%F duration= Groups taken from 
were alive and years 6.04y same source 
I Janumy resident in Tayside Baseline+ Cohort population but don't 
1988- in January 1987 follow-up Cohort =49% have any idea how 
December and who were ("cohort"): mean F they compare to each 
1995. either still alive in 3,403 66 other and nothing 
Tayside or who was adjusted for. 
had died at the end 
of the study. Mlno dm Baseline: 1,347 Baselin no data Baselin no data mean time no data No mention of% of 
emean e~ since outcome data 
obtained data from Baseline+ 57 28%F infarction = obtained. 
an agency follow-up: 3.5 y 
5,350 Cohort Cohort 
Overall study mean =46% 
population = 71 F 
263,175 
Haffner et a!. dm diabetic dmnoMI 890 mean 62.2% HTN 466M no data mean not Rating: II 
1998[8] people found age: 66.8% never smoked (52%), duration of specifically 
through a national 57.9 16.6% former smoker 424 F diabetes= mentioned not sure about loss to 
1982-1990 drug 16.6% current smoker 8.06 y but if follow-up and where 
reimbursement Mean: compare the 8 control patients 
8 yr follow-up register aged 45- BMI~29.2 population are accounted for. 
64 born and living T cholesterol numbers Given that the 
in I eastern (E) or =6.68mmoVL from original population of control 
I western (W) HDL~ 1.23 study[9] and patients with MI is 
University LDL~4.39 follow-up very small loosing 8 
Hospital district in Tri = 2.52 study it patients could have 
Finland that fasting plasma glucose = seems that an effect on the 
participated in a 11.67 nunoVL did not lose outcome. 
prior study from anydm 
1982-1984.[9] subjects. 
Non-diabetic= 
random smnple of 
subjects aged 45-
64 from 
population register 
of same areas in 
1982-1984. 
Recruited by 
postal 
questionnaire: 
diabetes 
participation 
83%E, 79%W 
control 
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participation MI no dm 69 mean 43.5%HTN 51 M no data not 
79%E85%W age: 33.3% never smoked (74%), specifically 
56.2 36.2% fanner smoker 18 F mentioned 
30.4% current smoker but if 
Mean: compare 
BMI~ 27,3 population 
T cholesterol numbers 
""7.07mmoVL from original 
HDL~ !.32 study[9] and 
LDL~4.93 fOllowHup 
Tri = 2.00 study it 
fasting plasma glucose= seems that 
5.4 mmoUL they lost 8 
control 
subjects 
Howard et al. Strong Heart dmno 2,008 mean Mean: 64%F none with mean at one point Rating: Ill 
2006[10] Study H study of CVD age= SBP ~ 131 prior duration of they mention 
CVD in 13 (98 had CHD at 57 DBP~ 77 CABG, dm"" 9.3 y "minimal need more info on 
1989-2001 American Indian baseline, 116 BMI~ 32 PTCA, loss to recruitment methods. 
tribes/conunw1itie hadCVD) HDL~43 document followHup" 
s in Oklahoma, LDL~ 103 edCAS for overall also do not have data 
Arizona, and the TG ~ 143 cohort on the CVD group. 
Dakotas. Fibrinogen = 
325 
aged 45H74yo at Fasting glucose 
baseline ~208 
2 hrOGIT"" 
able to assess dm 297 
status in4,465 of HbAIC~ 8.5 
4,549. CutTent 
smoking= 27% 
CVDno 58 no data no data at one point 
dm they mention 
of the 58,47 "minimal 
participants had loss to 
only baseline followHup" 
CHD for overall 
cohort 
Lee et al. ARIC study group. dmnoMI !460 no data 58.2%HTN no data no data mean no mention Rating: II 
2004[11] on 22.7% current smoker duration of of amount of 
biracial population mean 45.8% aspirin use dm= loss to concerned about the 
1987H Dec 31 from4 US age. 5.4% ACE! followHup. loss to followHup. 
1997 communities. range is 13.4% {3~block 96% 
45-64 18.1% other antiHHTN reported May have minor 
average 9 age range 45~64 onset after differences in 
years of mean values adjusted for 30yo. populations from 
follow~up Community age, sex, race, and center: different study 
cohorts selected Carotid IM groups due to 
75 
by probability thickness different recruiting 
sampling. In one 0.78 methods but was 
community the BMI~ 30.7 adjusted for. 
sampling was TCho1 ~ 219 
done by area HDL~44.4 
sampling, in the LDL~ 139 
other three it was SBP ~ 127 
done by sampling fibrinogen = 
age-eligible 319 
persons from Physical 
listings and then activity score 
identifYing their 2.33 
household.[12] Mlnodm 283 no data 46.6%HTN no data no data 
on 35.0% current smoker 
This analysis used mean 55.5% aspirin use 
13,790 people age. 55.0% ACE! 
from the original range is 31.1% {3-block 
cohort of 15,792 45-64 35.3% other anti-HTN 
recruited. (They 
excluded people mean values adjusted for 
with prior CV age, sex, race, and center: 
surgery, coronary Carotid IM 
angioplasty, stroke thickness= 
or cancer at 0.78 
baseline and those BMI~28.1 
that did not have TChol =222 
OM or CHD data) HDL~48.0 
LDL~ 146 
SBP ~ 118 
fibrinogen = 
317 
Physical 
activity score 
2.39 
Natarajan et Framingham Heart diabetes Male 103 mean- 4 7% current smokers N/A none with no mention. no data on Rating: III - fatal 
a!. 2003[13] Study and only 55 Baseline Means: MI, CI, or LTF, also flaw 
Framingham BMI~28.4 AP doesn't 
followed for Offspring study Tchol = 210 exactly not sure of end date, 
20 years from participants who HDL~41 define an was it that they 
baseline in were 35-74 years LDL~ 134 endpoint. followed everyone 
1970-1975 old during 1970- SBP ~ 143 The papers for 20 years or did 
1975 and had DBP ~ 86 simply says they set a 20 year 
"baseline exam" Female 75 mean 3 7% current smokers over 20 years period for the study 
where a clinical 58.9 Baseline Means: follow-up. such that the 
exam was BMI~29.1 participants have 
perfonned. Tchol = 247 slightly different 
Framingham HDL~49 follow-up times 
Study participants LDL~ 162 depending on when 
were recruited by SBP ~ 149 they entered the 
community DBP~ 85 study? 
76 
members serving CHDonly M 191 mean 46% cun·ent smokers N/A 61%MI 
on the advisory 59.4 Baseline Means: need loss to follow~ 
boards of the study BMI~26.8 16%CI up data. 
by word of mouth Tchol"" 223 
[14] and by HDL~41 23%AP Participants drawn 
sampling of LDL~ 147 from two different 
families from a SBP ~ 141 populations. 
local census.[l5] DBP ~84 
Female 109 mean 16% current smokers 25%MI 
For the FHOS the 64.4 Baseline Means: 
researchers BMI~26.9 9%CI 
attempted to Tchol ""'252 
contact all FHS HDL~ 54 66%AP 
families so that all LDL~ 166 
of their children SBP~l51 
could be DBP~ 84 
enrolled.[I6] 86% 
of the families 
were represented 
and 71% of the 
children in those 
families were 
included.[ 161 
Hu, et al. 2005 Independent PriorDM Male 496 mean Means: N/A No data No data End point Rating: II 
[17] population surveys only 53.0 BMI ~ 28.2 kglm2 data 
in 5 geographical DBP"" 90 mmHg collection random sampling of 
1972-2001 areas of Finland in SBP= 151 mmHg was population likely to 
1972, 1977, 1982, Setum Cholesterol"" 6.1 "practically reflect population of 
(Baseline 1987, 1992, and mmoVl complete" interest, but different 
cohort mean 1997. criteria for the 1972 
follow~up was Smoking: Never= 31.5%, and 1977 population 
12 years: b> 1972 and 1977 Past= 33.7%, Current= sample (not 
Incident a random sample 34.9% stratified). 
follow~up of6.6% of the 
mean was 7.7 population was Female- 466 mean- Means: N/A No data No data Apparently had good 
years selected. 52.4 BMI ~ 29.7 kglm2 rates offollow·up 
DBP ~ 88 
For each survey SBP ~ 152 
from 1982 onward Serum Cholesterol= 6.3 
an independent mmoVl 
random sample 
was drawn from Smoking: Never"" 79.2%, 
the population, the Past= 7.3%, Current= 
samples were 13.5% 
stratified so that at 
least 250 subjects Prior MI Male- 982 mean- Means: N/A No data No data 
of each sex and only 56.9 BMI=27.7kg/m2 
1 Oyr age group DBP~ 89 
were chosen in SBP ~ 147 
each area.[l8] Serum Cholesterol= 6.5 
77 
mmol/1 
Age range for the 
first 5 surveys was Smoking: Never= 16.8%, 
15-64, the 1997 Past= 43.6%, Current= 
survey included 39.6% 
ages 65~74 also. 
Female 326 mean- Means: N/A No data No data 
74~88% 58.3 BMI = 29.5 kg/m2 
participation rates. DBP = 90 nunHg 
SBP= 153 mmHg 
Serum Cholesterol= 6.8 
llllnol/1 
Smoking: Never= 78.5%, 
Past= 10.4%, Current= 
ll.l% 
Incident Male-981 mean Means: N/A No data N/A 
DM 60.1 BMI = 29.2 kg/m2 
DBP=94 mmHg 
SBP = 150 mmHg 
Serum Cholesterol= 6.5 
mmol/1 
Smoking: Never= 25.8%, 
Past= 26.9%, Cun·ent = 
47.3% 
Female-1,155 mean- Means: N/A No data N/A 
64.2 BMI = 31.0 kg/m2 
DBP=94mmHg 
SBP = 157tmnHg 
Serum Cholesterol= 6.7 
rmnol/1 
Smoking: Never= 84.2%, 
Past= 3.0%, Current= 
12.7% 
Incident Male- 1,308 mean- Means: N/A No data N/A 
M1 59.5 BMI = 26.5 kg/m2 
DBP=92mmHg 
SBP = 148 nunHg 
Serum Cholesterol= 7.0 
mmol/1 
Smoking: Never= 23.9%, 
Past= 22.3%, Current= 
53.7% 
78 
Female 566 mean Means: NIA No data NIA 
66.1 BMI = 27.5 kglm2 
DBP=92mmHg 
SBP = 155 mmHg 
Semm Cholesterol = 7.2 
nunoVl 
Smoking: Never= 80.6%, 
Past= 3.4%, Current= 
16.1% 
Juutilainen et exact same DMno Males 263 No data No data reported No data No data No data No data Rating: II 
al. 2005 (19] population as the CHD reporte reporte reported reported reported 
originial 1998 d d No mention about the 
1982-2001 Haffner study. [8] loss to follow-up. 
mean follow- dm = diabetic No table 1 with data 
up =18 years people found on various groups for 
through a national comparison 
drug (However we have a 
reimbursement limited idea from the 
register ages 45-64 Haffi1er article, 
born and living in although the CHD 
l eastern (E) or 1 comparison group is 
westem (W) different in this 
University Females 169 No data No data repmted No data No data No data article and the 
Hospital district in repotte reporte reported reported participants are 
Finland that d d divided into men and 
participated in a women 
prior study from and .. 
1982-1984.[9] although they did not 
publish the 
Non-diabetic= infonnation they did 
random sample of have it because they 
subjects aged 45- adjusted for risk 
64 from factors.). 
population register 
of same areas in 
1982-1984. 
Recruited by 
postal 
questionnaire: 
diabetes 
pruticipation 
83%E, 79%W 
79 
control CHDno Males 194 No data No data reported No data No data No data 
participation DM reporte reporte reported reported 
79%E85%W (51M1,87 d d 
angina, 137 
ischemic ECG 
changes) 
Females 236 No data No data reported No data No data No data 
reporte reporte reported reported 
(18 M1, 100 d d 
angina, 171 
ischemic EKG 
changes) 
Simons and Dubbo study mean Rating: fatal flaw, 
Simons 1998 ongoing age they do not tell us 
[20] prospective study >70 anything about the 
of CVD in elderly population studied 
Australians who 
were first can get some idea 
evaluated in 1988- from methods papers 
1989. but still unclear. 
(our question was 
not the primary 
focus of this 
study) 
98 months of 
follow-up 
completed 
80 
Lotutb eta!. 91285 US male DMno 2317 mean- Mean BMI 26.0 100% no data. No data on Rating: II 
2001 [21] physicians (US CHD 61.6 Percentages: male Authors state loss .to 
Physician Health Hypertensive"" 32.4 that "based followwup. only approx. 50% 
December 31 Study, PHS) aged High Cholesterol= 13.3 on the age Only response rate. 
1983 w Feb 1 40w84 years at Smoking status: Never= distribution searched 
1998. baseline that were 42.4, Past= 41.0, Current of the death No mention of lossw 
assembled in order = 16.6 participants, database, did towfollowwup or 
Mean followw to gather Vigorous exercise2 1/wk = it is likely not validate whether is 
up= 5 years participants for a 61.4 that the by any other differential or not. 
RCTtesting majority had method. However, this is 
aspirin and betaw type 2 likely small given 
carotene in the diabetes. "[21 outcome of death. 
prevention of CV J 
death and cancer 
(25% were 
subsequently 
randomiszed). 
letters of invitation 
were sent to CHDno 5906 mean MeanBMI 25.2 100% no data 
261248 male DM 63.9 Percentages: male 
physicians, Hypertensive= 33.3 
104388 responded High Cholesterol = 22.0 
and those with a Smoking status: Never= 
history of cancer, 30.1, Past= 57.3, Current 
stroke, liver = 12.7 
disease or renal Vigorous exercise:?: 1/wk = 
disease were 68.0 
excluded. 
Wannamethee Men from the DMonly 202 63.5 Mean BMI: 27.2 100% Recall of no data 99% followw Rating: I 
eta!. 2004 British regional noCHD Smoking status: Never= male Stroke: up 
[22] heart study (began 24.0%, Current= 12.9%. 5.9% 
in 1978) from one Physically active: 36.7% 
1992-2002 group general Nonwdrinkers: 22.1% Chest pain 
practice in each of RecallofHTN: 36.1% on 
24 towns in exertion: 
England, Wales, 6.4% 
and Scotland. 
Used those that Severe 
responded to a chest pain 
1992 questimmaire (possible 
(aged 52-74) as MI):3.5% 
their baseline 
(91% of survivors Breathless 
respon) ness: 
19.3% 
81 
Excluded ethnic Angina 379 65.5 Mean BMI: 26.6 100% Recall of no data 
minorities. only no Smoking status: Never= male Stroke: 
DM 17.5%, Current= 17.2%. 6.6% 
Response Rate = Physically active: 31.7% 
71% Non~drinkers: 23.7% Chest pain 
Recall ofHTN: 41.2% on 
All Type2 exertion: 
56.7% 
Severe 
chest pain 
(possible 
Ml): 
21.9% 
Breathless 
ness: 
49.9% 
Prior MI 547 64.7 Mean BMI: 26.5 100% Recall of no data 
noDM Smoking status: Never= male Stroke: 
16.2%, Current= 16.5%. 8.4% 
Physically active: 33.8% 
Non~drinkers: 22.5% Chest pain 
Recall ofHTN: 37.4% on 
exertion: 
52.3% 
Severe 
chest pain 
(possible 
Ml): 
51.7% 
Breathless 
ness: 
61.4% 
Whiteley et al. Census survey DMonly Men 74 55.4 SBP (mmHg) ]52 N!A no data Unable to <I% Rating: II 
2005 [23] identified all DBP (mmHg) = 86 distinguish emigrated 
people aged 45~64 % HTN > 160/90 mmHg) :::: Type 1 from during the Dropped over I ,000 
1972/1976- in two towns in 47 Type2 or to course of the of original 
1997/200 I (25 Scotland. Postal Serum Cholesterol determine study, thus pat1icipants due to 
years of invitation was sent (mmol/1) = 5.8 the duration outcome data incomplete data • did 
follow·up to eligible % Cholesterol >6 mmol/1 = of diabetes was not mention if the 
based on ent1y subjects, 79% in 46 ("highly available for loss was differential 
screening) Renfrew and 78% BMI = 27.3 likely ... that the rest. or not. 
in Paislev took 
-'-
% Current Smoker= 54 most had 
82 
part in the study. Women-77 55.8 SBP (mmHg) 158 N/A no data type 2") self~selection of 
DBP (mmHg) = 87 participants 
However only % HTN > 160/90 mmHg) = 
included 14,039 53 
participants (out of Serum Cholesterol 
15,406) in the (mmoV1) = 6.3 
analysis because % Cholesterol >6 mmoVI = 
they were missing 57 
data on others. BMI=26.9 
%Current Smoker= 42 
CHDonly Men 1,402 55.7 SBP (mmHg) 153 N/A no data 
DBP (nunHg) = 88 
% HTN > 160/90 mmHg) = 
50 
Serum Cholesterol 
(mmol/1) = 5.9 
% Cholesterol >6 mmol/1 = 
43 
BMI=26.0 
% Current Smoker= 63 
Women- 1,613 55.4 SBP (1mnHg) 156 N/A no data 
DBP (mmHg) = 88 
% HTN > 160/90 mmHg) = 
54 
Serum Cholesterol 
(mmoVI) = 6.5 
%Cholesterol >6 mmoVI = 
62 
BMI=26.6 
% Current Smoker = 48 
Vaccaro eta!. Used screening OM only 4809 49.1 SBP (mmHg) 137.8 100% no data no data not Rating: U 
2004 [24] data (from 1972~ DBP (mmHg) = 86.0 Male mentioned. 
1975) on 9434 % of Patients with Would tend Potential for loss~of-
1972-1999 men excluded SBP<l30mmHg and to assume follow-up 
from the MRFIT DBP<85mmHg = 28.4 that data is 
trial due to prior Serum cholesterol (mgldl) relatively 
CHDorDM. =213.8 complete 
current smoker= 36.0% given that 
These men were Nonwhite"" 16.9% they used 
taken from varied population 
populations, ie. mortality 
from employees at statistics for 
a worksite to outcome 
volunteers.[6J data. 
They were not 
sought from 
clinics that 
83 
focused on CV Prior MI 4625 50.3 SBP (mmHg)- 131.9 100% no data 
risk factor only DBP (mmHg) = 85.0 Male 
reduction or % of Patients with 
chronic disease SBP<l30mmHg and 
management. [ 6] DBP<85nunHg = 37.5 
Serum cholesterol (mg/dL) 
= 228.8 
current smoker= 37.4% 
Nonwhite= 7.5% 
Becker 2003 Hoom study~ Men with 63 63.8 BMI-27.4 NIA no data %Newly I7 Rating: II 
[25] Dutch population DMonly SBP (nunHg) = I46.0 diagnosed pmticipants 
(references of based cohort DBP (1mnHg) = 87.3 DM=65 were large Joss to follow~ 
Hu 2005) randomly selected %HTN=46.0 completely up for CVD events, 
from the % HTN med = 20.6 mean lost to the patients with OM 
I 989-2000 population register % lipid lower med = 0 Diabetes follow~ up that were not LTF 
in the town of Total cholesterol (mmol/1) duration= (0.6%) seemed to have 
Hoom. 71% = 6.2 7.0 (4.6- slightly longer 
agreed to HDL (mmol/1) = l.l I !.3) Did not have duration of disease. 
participate~ 56 LDL(mmoVI)=4.I infonnation 
non-caucasians Triglycerides (nunol/1) = about Also LTF more 
and 23 participants !.6 nonfatal CV people from the prior 
with missing data HbAlc %= 6.9 events CVD group than lhe 
excluded to result Smoking status %: (morbidity) OM group. 
in a study Never= 17.7,Fonner= from 612 
population of 59.7, Current= 22.6 participants 
2,46!. Women 90 66.0 BMI 29.! NIA no data %Newly (24.6%) 
with OM SBP (mmHg) = I45.9 diagnosed because they 
only DBP (1mnHg) = 82.8 DM=58 did not give 
% HTN=60.0 pennission 
% HTN med = 37.8 mean or had 
%lipid lower rued= 2.2 Diabetes moved out of 
Total cholesterol (mmol/1) duration= Hoom (185, 
= 6.9 5.6y (2.2- 7.4%). 
HDL (mmol/1) = 1.2 I4.2) These 
LDL (1mnoVI) = 4.6 participants 
Triglycerides (mmol/1) = were not 
!.9 included in 
HbAlc %= 7.2 HR analysis 
84 
Smoking status: for 
Never= 61.4, Fonner= morbidity. 
18.2, Current= 20.5 
lmpt. 
comparisons 
between all 
Men with 178 63.4 BMI 26.2 N/A no data 
participants 
prior SBP (mmHg) = 136.9 and LTF 
CVD only DBP (nunHg) = 83.6 participants. 
% HTN = 57.6 
% HTN med = 48.9 
8.5% of 
%lipid lower med = 4.5 
participants 
Total cholesterol (mmol/1) were dm, 
= 6.7 
SJ% ofLTF 
HDL (mmolll) = 1.1 wereDM. 
LDL(mmoV1)=4.7 16.2% of 
Triglycerides (mmol/1) = 
1.6 
patticipants 
HbA1c o/o= 5.5 had prior 
Smoking status: 
CVD, 14.2% 
Never= 8.4, Fonner= 
ofLTFhad 
56.2, Current= 35.4 
priorCVD. 
54.1% of 
Women !56 64.1 BM1 27.2 N/A no data participants 
with prior SBP (mmHg) = 136.5 had newly 
CVD only DBP (mmHg) = 80.6 diagnosed 
%HTN= 54.5 DM whereas 
% HTN med = 50.6 65.3% of 
%lipid lower med = 6.4 LTFdid. 
Total cholesterol (mmol/1) 
= 7.0 A vg duration 
HDL (mmol/1) = 1.4 ofDM in 
LDL (mmoV1) = 4.8 particpants 
Triglycerides (mmolll) = was 6.4y, in 
1.4 those LTF 
HbAlc %= 5.5 was 5.9y. 
Smoking status: 
Never= 51.3, Fonner= 47.7% of 
25.6, Cun·ent = 23.1 participants 
were men, 
40.2% of 
LTF were 
men. 
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Natarajan et NHANES I coh01t Men with 113 58.2 BMI 26.2 N/A no data no further At the 1992 Rating: II 
al. 2005 [26] data(~ 14,407 ROM %Current smokers== 43.6 data survey 90% 
participants). only Total cholesterol (mg/dL) of the No specific loss to 
1971-1992 ~ 229 members of follow-up data from 
1971-1975, u.s. % HTN == 58.4 the original this exact cohort, was 
(17-21 years civilian %White= 89.2 coh01t of it differential? 
of follow-up) noninstitutionalize 14,407 
d population. people that 
Oversampled the Men with 64 59 BMI~26.3 N/A no data were not 
poor, women of LDM only %Current smokers== 24.7 known to be 
childbearing age Total cholesterol (mg/dL) deceased had 
and those 65 years ~ 231 been 
and older. % HTN == 69.1 traced.[28] 
This analysis was %White== 81.0 No data 
restricted to the specifically 
individuals aged on the 
35-74 at the Men with 369 58.9 BMI-25.7 N/A no data restricted 
baseline exam.(= MI only %Current smokers"' 28.4 cohort from 
10,871 Total cholesterol (mg/dL) this study. 
participants) ~233 
This cohort was 
%HTN= 59.9 
%White= 94.5 
selected as a 
national 
probability sample Women 200 57.9 BMI- 28.0 N/A no data in order to 
with %Current smokers= 26.1 
represent the 
ROM Total cholesterol (mg/dL) 
entire U.S. 
population. [27] only ~ 231 % HTN = 69.8 
They were % White= 82.3 
recruited by use of 
media and mailers. 
[27] Women 85 63.8 BMI-26.9 N/A no data 
withLDM % Cun·ent smokers= 12.8 
only Total cholesterol (mgldL) 
~ 239 
% HTN=85.9 
%White= 85.2 
Women 225 60.1 BMI-27.8 NIA no data 
withMI % CUtrent smokers= 20.7 
only Total cholesterol (mg/dL) 
~246 
%HTN,65.2 
%White= 90.1 
. 
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Measurement Table 
Source Measurement Measurement of Potential for Measurement Bias 
Measurement of Exposure of Outcome Potential and Rating 
Confounders (eaual, valid, reliable) 
Hu et al. 2001[1] DM self-reported mailed questionnaire every 2 years, Deaths were reported by next of self-reported Rating II 
limited to diagnosis after age 30. kin or through the National Death questionnaire every 2 
Index. years, used 1986 data Measurements equal between groups. 
Mailed Supplementary questionnaire to confinn if at to represent the overall 
least l of the following: (1) l or more classic Obtained copies of death cohot1 Attempted to validate outcomes 
symptoms plus fasting glucose at least 140mg/dL certificates and medical records through medical records. 
(7.8mmoVL) or random plasma glucose at least 200 to detennine cause of death. 
mg/dL (11 .OmmoVL); (2) at least 2 elevated glucose Did not do physical exams however 
levels on different occasions (see above for levels) in Fatal CHD was con finned by self report more reliable in cohort of 
absence of symptoms; or (3) treatment with hospital records or autopsy if nurses due to medical knowledge. 
hypoglycemic medication CHD was listed as cause of death 
Did a blinded validity test on62 participants = 98% on death certificate and evidence Yet, some issues with CHD 
valid of previous CHD was available. measurement. Poor confinnation of 
MI Women were asked about having angina pectoris, JfCHD was listed on certificate prior Ml with medical records 
history ofCABG/angioplasty, and/or MI. Only report but no records were available it (reliability) and considered all 
ofMI was considered as a history ofCHD. was considered "probable fatal sudden deaths as fatal CHD 
CHD" (14.7% of fatal CHD (validity). 
self report of ptior MI mailed every 2 years cases). Also included sudden 
Confirmation through medical record review deaths as fatal CHD (12.3%) Did not screen non-diabetic group for 
according to "strict" diagnostic criteria was 68%- glucose intolerance. 
82%. Most of the nonconfirmed cases had coronary Deaths for all CVD events 
disease but did not meet criteria for MI. included: ICD-9 codes 390-459, 
795 
Booth et al. DM Ontario Diabetes Database Hospital records for the main None measured Rating fatal flaw 
2006[3] -claim for one or more admission to a hospital or two diagnosis OfMI (ICD9 410.0-
or more claims for visits to a physician( within 2 years) 410.9) or Stroke (ICD943 1,434, Did not assess those that did not go 
which lists a diagnosis of diabetes. 436) and to identify in hospital to the physician (i.e. undiagnosed 
(Noted that this is 86% sensitive and 98% specific for deaths. DM). 
patients in whom diabetes was recorded in primaty 
care charts.) Registered persons Database Only used recent Hx of MI - some of 
used for deaths that took place the DM group could have had MJ in 
M1 Hospital records from the 3 years before April I 1994. outside of the hospital the past 
All cause mortality used as a Used non-valid sutrogate for CHD 
surrogate marker for CHD deaths deaths. 
due to lack of clarification in the 
databases. 
Cho eta!. DM Self-repmted mailed questimmaire, excluded men that Deaths were documented by self response from Rating II 
2002[4] reported having type l and those that reported having responses to questionnaires by mailed questionnaires 
dm diagnosed before age 30. family members or the postal every 2 years Concemed about validity of self 
Supplementary questimmaire sent if reported dm - service, also the National Death report of MI. 
"continued dm" from this questiom1aire if any of the Index was searched. 
following: l) one of more classical symptoms plus Did not screen non-diabetic group for 
fasting glucose~ 140 mg/dl or a random glucose~ Searched medical records if a presence of dm. 
200 t;g/dl; 2) at least 2 elevated plasma glucoses on death from CHD (lCD9=41 0-
87 
different occasions in the absence of symptoms; 3) 414) or CVD (ICD9 390-459, Note: if a person with only dm at 
treatment with hypoglycemic medications. 795) was identified. baseline developed a non~fatal MI 
blinded validity test comparing to medical records in they were moved to the DM and MI 
59 cases""' 97% Obtained death certificates for category resulting in twice as mm1y 
used self~reported dm for primary analysis and deaths that were not confinned deaths being assigned to this 
confirmed dm for secondary analysis category on the updated data set. 
MI self~repotted questionnaire (overall findings similar to baseline) 
cited that this method was validated in studies among 
female nurses and male physicians 
Eberly, et a!. DM If at;;::: 1 of 6 trial visits a participant reported being on Post RCT mortality through Dec Patients were brought Rating- I 
2003 [5] insulin or and oral hypoglycemic medication or if his 31 1990 was determined by the to clinical center for 
measured fasting plasma glucose was> 126 mg/dl. National Dealth Index records. medical history, Measurements applied equally. All 
NF-CVD Any of the following recorded before the 6th annual Death certificates were then physical exam, and cases were incident cases so the onset 
visit: obtained and cause-specific blood tests ~ all blood was during a similar time frame. 
( 1) coronary bypass surgery ~ self~reported mortality was coded tests were sent to a 
(2) nonfatal stroke- observation of hemiplegia or independently by 2 people with a central lab Measurements for both exposure m1d 
hemiparesis made at any annual visit by a MRFIT third to adjudicate disagreements. outcomes valid. 
physician resting supine EKGs 
(3) clinical nonfatal MI ~annual visit EKG compared Deaths froml991-1998 (ICD~9) taken at visits 3~6. Bringing patients in for physical 
with eah participant's baseline EKG = change in and 1999 (ICD-10) were Recorded visually and exams and doing blood tests at a 
baseline Q~wave or by physicim1 review of detennined by the National Death by computer ~ central lab vety reliable. 
hospitalization records, serum enzyme levels and Index Plus. discordm1ces 
EKGs. independently 
(4) silent MI on EKG CVD mmtality = ICD~9 350-459, adjudicated by two 
lCD- I 0 100- I 99 blinded cardiologists 
CHD mortality= ICD~9 41 0~414 Did not measure during 
and 429.2, ICD-10 120-125. the 18 year long 
follow~up study = only 
have baseline risk 
Evans, Wang, DM records from the DARTS/MEMO Collaboration Cross~sectional: age and sex measured Rating: II 
and Morris 2002. Cross~sectional: total mortality, hospital from DARTS/MEMO 
[7] those patients with type 2 diabetes (excluded type 1 = admission with primary diagnosis collaboration data not entirely sure: don't know exactly 
those diagnosed before 35 years old and requiring ofMI (410.9). how reliable the collaboration data is 
insulin treatment) before index date. no other risk factors ~ authors cite studies that show its 
excluded if in their MI group Cohort: measured validity and reliability. 
total mortality 
Cohort: cardiovasular mortality (from Not sure why did not include 
type 2 patients diagnosed between Janua1y 1988- death certificate) secondary diagnosis of MI in cross~ 
December 1995. excluded if had MI hospital admission for MI (any sectional data 
MI records from the DARTS/MEMO Collaboration admission with primaty or 
Cross Sectional: secondmy diagnosis code of Assume that baseline cohorts were 
patients who had an inpatient hospital admission with 410.9). mutually exclusive,,. 
Ml (ICD~9 410.9) between January 1980 to December 
1995 excluded if in their DM group. Wanted to make sure that cohort 
populations had similar date of onset. 
Coho1t: of exposure between groups. 
had to have a first hospital admission for MI between 
January 1988~December 1995. Excluded if had MI 
between Jan l980~Dec 1987 and those that died within 
88 
28 days from index date of MI. Also excluded 
patients with type 2 dm that were diagnosed on the 
same day as their first MI. 
Haffner et al. DM diagnosed from the FiiUlish Social Insurance All medical records of the Brought participates in Rating: I 
1998[8] h1stitution register of patients with diabetes who subjects who died and those that for a clinical history 
receive reimbursement for drugs. Excluded patients reported on a questionnaire sent and exam. Potential to miss DM patients that 
with type 1 dm by CMpeptide levels, and those that out in 1990 that they had been were not receiving medication. (ex. 
were diagnosed before age 30[9]. Excluded patients if hospitalized for acute chest pain Interview: smoking, 8 patients were excluded from 
their OGTI did not confirm dm[9]. None of the type or stroke symptoms were alcohol intake, physical control population because they were 
2 patients included in the study had a history of reviewed by one of the activity, use of diagnosed with dm during the 
ketoacidosis. investigators. medications, and any clinical history/exam). 
M1 All medical records of subjects that reported an history of chest pain. 
admission to a hospital for chest pain suggestive of Received death certificates, if 
coronary heart disease during a medical interview at possible also used hospital and Blood pressure 
the university hospital were reviewed by 2 autopsy records to classify cause measured in equal, 
investigators using the WHO criteria for verified of death. valid fashion: 
definite or possible myocardial infarction (based on considered HTN if 
chestMpain symptoms, EKG changes, and enzyme Used a computerized hospitalM systolic >160, 
determinations). discharge register was used to diastolic>95 or on 
check for hospital admissions of medication to lower 
all participants in baseline study M BP. 
med records checked if 
suspicious for MI/stroke. 8am blood draw after 
12 hour fast for 
Modified WHO criteria, as used glucose, lipids and 
in the baseline study, were used lipoproteins. Sent to a 
to determine MI. central lab. 
Who definition of definite and 
possible stroke was similar to 
that used at baseline - clinical 
syndrome of neurological defect 
lasting >24 hours without other 
explanation. 
Death from stroke == ICDM9 codes 
431-434. 
Howard et al. DM Collected blood samples at medical visits. Diagnosed Between the baseline exam and personal interview with Rating 1 
2006[10] dm if any of the following: 31 Dec 2001. each subject collected 
(1) fasting glucose;::: 126 mg/dl information on 
(2) taking an oral hypoglycemic agent or insulin Deaths were identified through demographics, medical 
(3) report of physician-diagnosed diabetes contact with family, ttibal, and history, medication use, 
IHS records. and health-related 
CVD prior Ml, ptior coronary revascularization (PTCA or habits. 
CABG), previous angiographic documentation of Nonfatal events were identified at 
coronary stenosis or pathologic Q waves on a the examination or between Blood pressure was 
collected EKG or documentation of previous stroke at exams by mmual surveillance. measured (HTN == ;?:140 
the baseline exam. Medical records were reviewed. systolic, ;::: 90 diastolic, 
oruseofanti-HTN 
Nonfatal CHD == Ml, CABG, medication). 
PTCA, or new angiographic 
89 
documentation of significant 
coronary stenosis. 
Nonfatal CVD = CHD and 
stroke. 
Fatal CHD =fatal Ml, sudden 
CHD death, or fatal CHD. 
Fatal CVD"" fatal CHD, fatal 
stroke, or death due to 
aortic/peripheral arterial disease. 
Lee eta!. dm (1) fasting glucose level2:::126 annually contacted by telephone home interview for Rating: I 
2004[11] (2) nonfasting level2:::200 to identify all health habits, 
{3) use of hypoglycemic agents hospitalizations/deaths. Searched demographics, and 
(4) history of physician diagnosed dm. lists of discharges from local medical histories. 
M1 evidence of prior MI by EKG or a self~reported hospitals. If hospitalized for 
history of physician-diagnosed heart attack. potential MI or stroke searched Clinical exam for blood 
records. pressure (HTN = 
SBP2:::140, DBP2:::90, or 
Deaths identified ilum death use ofanti~HTN 
certificates- out of hospital medication), 12 hr 
potential CHD deaths were fasting blood tests, 12 
verified through an interview leadEKG, 
with next of kin and a anthropometries, and a 
questionnaire filled out by the B~mode ultrasound of 
patient's physician. the carotid artery. 
CHD were validated by 
committee of physicians, CVD 
events were validated by a 
combination of a computer 
algorithm and physician review. 
CHD events = definite or 
probably hospitalized MI or 
definite fatal CHD. 
strokes = definite or probably 
hospitalized stroke. 
CVD death = death certificate 
ICD-9 codes 390-459. 
Natarajan et aL Diabetes In the original Framingham study "probable diabetes" CHD mortality all participants had a Rating: II 
2003[13] = 2 casual plasma glucose values > 150 mgldL or the clinical investigator panel medical history and 
use of hypoglycemic medications. reviewed records that included medical exam between Did not mention the exact cut off for 
All "probable diabetics" had records reviewed detailed histmy, clinical findings, the years 1970~1975. diagnosis of diabetes for the original 
(including OGTTs) by investigators, final diagnosis EKGs, autopsy reports, and death Framingham population- if use 
was made based-on corroborating evidence. certificates. Sudden CHD death HTN= SBP>l40, criteria for probable diagnosis then 
= within an hour of onset of this is not a valid measurement. 
90 
Fasting glucosU 140 or use of hypoglycemic agents symptoms. DBP2::90, or use of anti-
defined diabetes in the Framingham Offspring Study. HTN medication Not sure how they obtained CHD 
CHD Myocardial Infarction, Coronary Insufficiency (Cl), or measures, did not attempt to confirm. 
Angina Pectoris (AP) Including Cl and AP makes this 
Divided results analysis into two groups ofCHD (I) group a lower risk group than only 
those with CI or AP only and (2) those with MI only prior MI. Self-report of AP seems 
very wrreliable. 
Hu, eta!. 2005 DM Prior OM - Prior report of any of the following: followed for endpoints through a self-reported mailed Rating: II 
[17] ( 1) self-report of DM on a mailed questiotu1aire computerized register linkage questionnaire. 
(2) hospital discharge diagnosis ofDM (from the using the personal identification National Health Insurance Statistics 
National Hospital Discharge Register) number assigned to every At the study site and Mortality statistics are relatively 
(3) approval for free-of-charge medication for diabetes resident in Finland. research nurses reliable. 
(from the National Social Insurance Institution's measured blood 
Register) Mortality data were from pressure, ht, and wt. A Self-report is less reliable. 
Statistics Finland. venous cholesterol was 
Incident cases were defined if either (2) or (3) obtained for total Good measw·ement of potential 
occurred during the study period. lCD 8,9, and 10 codes were used cholesterol (no mention confounders. 
for coding the cause of deaths. of fasting). All 
excluded patients with Type I from analysis (not sure samples analyzed at the Not sure if the incident diagnoses of 
how) Codes 390-459 and I00-199 were same lab. Analysis MI or DM were free of the other 
M1 Prior MI Prior repott of any of the following: classified as CVD deaths. methods changed and disease at baseline. 
( 1) self-report of MI on a mailed questionnaire adjustment was made 
(2) hospital discharge diagnosis ofMI Codes 410-414 and 120-125 were to allow for The exposure measurements are very 
coded as CHD deaths. comparisons. broad/sensitive, thus may lead to 
Incident cases included those that occun-ed during the over-diagnosis of initial disease and 
study period and met criteria (2). may capture people with lower 
severity of disease (i.e. diet 
controlled DM). No laboratory 
measurement of exposures. 
Juutilainen et a!. DM diagnosed from the Firmish Social h1surance lnfonnation of vital status and Brought participates in Rating~ I 
2005[19] Institution register of patients with diabetes who copies of death certificates were for a clinical history 
receive reimbursement for drugs. Excluded patients obtained from the Cause-of- and exam. 
with type 1 dm by C-peptide levels, and those that Death register, If available 
were diagnosed before age 30(9]. Excluded patients if hospital records and autOpsy Interview: smoking, 
their OGTT did not confinn dm[9]. None of the type results were also reviewed. alcohol intake, physical 
2 patients included in the study had a history of activity, use of 
ketoacidosis. CVD death= ICD-8 codes 390- medications, and any 
CHD All medical records of subjects who repotted in an 459 history of chest pain. 
interview that they had been admitted to the hospital 
for chest pain symptoms were reviewed in a CHD death = ICD~8 codes 410- Blood pressure 
standardized fashion. Hospital records of those who 414 measured in equal, 
reported that they had been hospitalized for CVD were valid fashion: 
reviewed. considered HTN if 
systolic 2::160, 
Four categories were defined: diastolic~95 or on 
(l) prior MI verified at the hospital (modified WHO medication to lower 
criteria for definite or possible MI) BP. 
(2) angina pectoris (Rose criteria) 
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(3) ischemic ECG changes (Whitehall changes per Sam blood draw after 
Minnesota coding) 12 hour fast for 
( 4) any evidence of prior CHD included in the above glucose, lipids and 
categories lipoproteins. Sent to a 
central lab. 
Simons and DM Previously received a diagnosis of dm from a hospital admissions with any Rating: III 
Simons 1998 physician, if they were using medication for diabetes, manifestation of coronary hemt 
[20] or if they had a single fasting plasma glucose level of disease (ICD·9 41 OA 14 ). self· report less valid than if did chart 
at least 7.8 mmoVI. review. 
CHD Fasting glucose ofless than 6.lmmol/l. positive 
responses to a myocardial·infarction questionnaire, unsure of what tisk factors were 
positive responses to the Rose angina questionnaire, or measured or how they measured 
on diagnostic ECG changes. them 
Lotufo et al. DM Baseline questionnaire asking if participant had a Endpoints: self-repott of blood Rating: II 
2001 [21] history of DM. Self-report not validated by medical (I) all deaths pressures, medication 
records. No infonnation was collected about the type (2) CHD deaths (ICD-9 codes treatment for coronary Self-report of prior disease not 
or duration of DM. 410-414). risk factors, cigarette validated by records, nor were there 
CHD Baseline questioMaire asking if had a history ofMI or smoking, evercise, and any clinic visits or labratory data to 
angina. Self-report not validated by medical records. deaths were identified through frequency of alcohol validate. 
systematic searches of the intake. BMis were 
national death index, death calculated from self- Self-report somewhat more valid 
certificates were obtained from reported height and given that the study population 
state agencies for all deaths that weight. consists of medical physicians only. 
occurred before Feb l 1988. Did a validation sample with a 95% 
rate of confirmation of CHD events 
in the randomized uhase of the PHS. 
Wannamethee et DM Men who recalled a doctor's diagnosis of diabetes at Death infonnation was collected All from self-reported Rating: III 
al. 2004 [22] the 1992 questionnaire and men with continued through the established tagging questionnaires. 
diabetes based on general practitioners' records procedures through the NHS. Did not use any objective measures 
between initial exam and 1992. of ptior history of DM or Ml and did 
PriorCHD Men that recalled a doctor's diagnosis ofCHD (MI or Non-fatal events were obtained not do a clinical exam for risk 
angina) at the 1992 questionnaire and those who had a from general practitioners, by factors. 
major non~ fatal Ml event or angina event before 1992 biennial review of the patients 
based on the regular surveillance of general notes through to the end of the Prior history and outcome 
practitioners' records (including hospital and clinic study and from postal classifications quite broad since they 
correspondence). questionnaires. include patients that self-report 
without validation through records or 
The participants were then divided into two groups (I) Fatal CHD events = death with testing. 
MI or (2) angina ICD-9 codes 410414. 
Non~ fatal MI =WHO criteria. 
Fatal stroke= ICD-9 430~438 
coded deaths 
Non~ fatal stroke= events that 
produced a neurological defect 
for l!reater than 24 hours. 
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Whiteley et a!. DM self-reported in 190 subjects. Did a random blood Death records retrieved from the smoking habit and Rating: Ill 
2005 [23] glucose in 4,702 subjects. RBG was~ 11.1 1mnol/l Registrar general in Edinburgh. social class were 
(~200mg.dL) in 38 additional subjects. Unable to Three mutually exclusive cases measured by self- Self-repmt of OM unreliable, likely 
distinguish Type 1 from Type 2. of death: report. Clinical missed many that had OM. (would 
CHD If they responded positively to the Rose Angina (I) CHD: !CD-9 codes 410-414 measurements included overestimate risk because would miss 
questionnaire, have severe chest pain lasting >30 min, (2) other vascular deaths: stroke blood pressure, BMI, less severe cases) Also, should have 
or one or more of the following Minnesota codes ( 1.1- ICD-9 codes (430-438) and other and nonfasting plasma applied diagnostic criteria of 
1.3, 4.1-4.4, 5.1-5.3 or 7.1) on a six-lead EKG vascular causes (390-459) cholesterol. checking blood glucose to all 
(3) all nonvascular deaths (all participants. 
other ICD-9 codes) 
Also, may have over classified prior 
CHD as well given the broad 
definition. These patients with CHD 
are likely to be at lower risk of future 
CHD than only those with prior MI. 
Outcomes measures reliable and 
valid. 
Vaccaro et al. DM self-report of using medication for diabetes Prior to 1979 used mortality data self-report of age, Rating: III 
2004 [24] from the US Social Security cigarettes smoked per 
MI self-report of being previously hospitalized for heart Administration. From 1979-1990 day, and ethinicity. Missed many less serious cases of 
attack. the US National Death Index was OM that did not need to be treated 
used and from 1990-1999 the Clinical visit measured with medications(= overestimated 
National Death Index-Plus blood pressure and the risk from DM). 
service was used. non-fasting cholesterol. 
Also did not validate self-repo1t of 
Total CVD deaths = ICD-9 codes Income data were later exposure with medical records or 
390-459. estimated by matching objective testing. 
the zip code of 
Death from MI = code410 residence with median Outcomes measures reliable and 
' family income data valid. 
' 
Death from other CHD = 411- from the 1980 census. 
414,429.2 
Death from stroke= 430-438 
Becker 2003 [25] DM fasting blood sample and a 75g oral glucose tolerance Data on the participants vital Serum lipids and Rating: Not applicable 
(references ofHu test was administered, results were sent to a conunon status were collected from the lipoproteins were 
2005) lab. Participants were classified to have DM by the mortality register of Hoom. For drawn and sent to a Very broad defmition ofCVD, 
1985 WHO criteria. all participants who died, the common lab. Blood includes patients with very mild 
CVD Self-reported history or one or more of the following: cause of death was extracted pressure was measured disease (angina)= lowers CVD risk 
acute myocardial infarction, coronary bypass surgery from the medical records of the twice during one visit. and also includes people with TIA 
or angioplasty, angina pectoris, transient ischaemic general practitioner and the Patients were and CV A. Also, all based on self-
attack or stroke, intermittent claudication, or the use of hospital of Hoom considered to have report without objective validation, 
nitrates. HTN if the SBP was likely that this is not very reliable or 
For participants that moved out ~160 mmHg or if the valid. 
of Hoom the data was obtained DBP was~ 95 mmHg 
from the new municipality. and/or they were using Definition of DM is very good as is 
anti-HTN medicine. the measurement of potential risk 
Nonfatal CV event data was BMI was measured factors. 
obtained from medical records of from Ht. and Wt. 
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U1e hospital of Hoom. Nonfatal measured at clinic visit. Overall doesn't answer our question 
CV events = coronary heart Self-report of smoking because did not run separate analyses 
disease (prolonged typical chest status witl1 only CHD as an outcome ... 
pain, ECG changes, enzymes, 
and PCT A/CABG), CHF, TIA, 
CVA,orPAD. 
CV mortality= ICD-9 codes 390-
459 and 798 (sudden death). 
Cardiovascular events were 
defined as the first fatal or 
nonfatal event during follow-up. 
Natarajan et al. DM Self-report of physician diagnosed diabetes. Also Participants or their proxies were Mobile medical units Rating: II 
2005 [26] asked when it was first diagnosed. RDM = if diabetes contacted i.nl982-1984, 1986, were taken to the 
duration at baseline was less than I 0 years. LDM "" if 1987, and 1992. If applicable, participating towns to Self-report will underestimate the 
duration of diabetes at baseline was l 0 years or death certificates were obtained collect subjective and prevalence of both prior MI and DM. 
greater. on those tl1at died (97.3% of objective data on CV This will likely cause the populations 
Did not separate Type I and Type II. those with DM at baseline and risk factors. to be higher risk that the general 
MI participant self-report of physician diagnosed hemt 96.5% of those without DM at population given that less serious 
attack. baseline). smoking status was disease will be missed. Also criteria 
classified by self- for the diagnosis of DM has became 
Searched national death index, report. more strict since this data was 
social security administration obtained, contributing to the number 
mortality file, and health care BP was obtained, HTN of undiagnosed, by today's standards, 
financing administration (to help was defined as DM patients in this sample. 
determine location ifmoved).[28] SBP;?:l60mmHg, 
DBP;:o:90mmHg, or use Outcomes and CV risk data were 
Death certificates were used to of anti-HTN meds. well measured. 
detennine the cause of death, if 
ICD-9 code was 410414 they Total cholesterol was 
were considered to have had fatal measured and sent to a 
CHD. central lab. 
BMI was calculated 
from measured weight 
and height. 
Ethnicity was 
categorized as 
white/nonwhite. 
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Potential Confounders/Analysis Methods Table 
Study Analysis Adjustment methods Potential confounders Potential confounders (not Potential for confounding (I~ III) and 
used (adjusted) adjusted) Justification. 
Huetal.2001[!] (I) baseline pooled logistic ~Age (5 yr category) History of HTN Rating lll 
(2) baseline+ follow~up regression (defended ~Time (independent 2 year History of High Cholesterol 
cases this over Cox blocks of person~time were Medications HTN and High Cholesterol not adjusted for 
regression because pooled) (not solely causal intennediates thus should 
Outcome Rates calculated as used short time - BMI (did subgroups analysis of be adjusted for). Mentioned that these were 
number of incident cases intervals and low ~Menopausal status inc. these two groups) further adjusted for and that it did not change 
divided by person~years of probability of hormone usage RR for total mortality but somewhat 
follow~up. outcome) ~ Cigarette smoking attenuated the RRs for fatal CHD. 
~ Parental history of MI 
Relative Risk: Outcome rate Both groups adjusted before age 60 
among groups/rate among for same variables 
women with neither (EtOH use adjusted for but 
condition with adjustment. not included in final model, 
did not change outcomes) 
Booth et al. Rate of fatal or non~fatal Cox proportional ~Age All others Rating fatal flaw 
2006[3] coronary events in people hazards model ~Sex 
with DM compared to No adjustment for most confounders, plus 
people with previous MI. don't have any data on the populations. 
Hazard Ratios 
Cho et al. ( l) baseline Cox proportional ~Age History of HTN Rating lll 
2002[4] (2) baseline+ follow~up hazards regression ~Time History of High Cholesterol 
cases jointly stratified by ~ smoking status Medications HTN and High Cholesterol not adjusted for 
age in months at the -BMI (not solely causal intennediates thus should 
Outcome Rates: calculated start of follow~up and ~physical activity be adjusted for). 
as number of incident cases calendar year of ~ parental history of MI 
divided by person~time of current questionnaire before age 60 
follow~up. cycle. ~EtCH intake 
~Vitamin E supplement use 
Relative Risk: Outcome rate 
among groups/rate among 
women with neither 
condition with adjustment. 
Eberly, et al. Death counts, death rates per Univariate and RCT status (special Statins Rating I 
2003 [5] 10,000 person~years, and multivariate-adjusted intervention/usual care) 
Kaplan_ Meier Curves. proportional hazards age "additional adjustment for 
models stratified by race during trial.B~blocker use 
Hazard Ratios: clinical center were baseline and 6th annual visit gave similar results" 
( l) comparing both groups carried out for each smoking status 
separately to those without mortality type (total, EtOH 
either condition CVD,andCHD Heart rate 
(2) comparing those with Heart~rate adjusted QT 
NF~CVD to those with dm No adjustments for interval 
multiple comparisons height 
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) parental dm 
parental hemt disease 
proteinuria 
trial averaged BMI, SSP, uric 
acid, TGs, HDL, LDL, and 
thiazide use. 
Evans, Wang, Risk ratios for hospital Cox proportional age all others Rating - iiltal flaw 
and Morris 2002. admission for MI, total hazards model sex 
[7] mortality, CVD mortality. did not adjust for potential risk factors aside 
from age and sex nor do we have data 
Kaplan· Meier sutvival showing if risk factors are equivalent between 
curves in cohort study. groups (unlikely) .. 
Haffner et a!. Incidence rates Univariate and age parental histmy Rating II 
1998[8] Hazard ratios Multivariate Cox sex BM1 
Kaplan-Meier survival regression models. smoking status medication use (anti-HTN, 
curves HTN statins) 
LDL EtOH use 
HDL .-ace 
triglycerides 
Howard eta!. b1cidence rate (events per Cumulative age everything except age Rating: fatal flaw 
2006[!0] I ,000 person-years) Incidence was age 
10-y cumulative incidence adjusted by the direct diabetic pmticipants stratified did not adjust for confounding factors 
(in percent, number of new methods using the into four strata depending on 
events over 10 years divided age distribution of number of risk factors - prior When stratified did not stratify both groups 
by the number of the entire SHS CHD participants were not. equally. 
participants at risk at sample Risk factors included were: 
baseline) sex, LDL>IOO, albuminuria, reported results in cumulative incidence (not 
Cox proportional HTN, HDL<40, appropriate, should have used incidence rate 
Hazard ratios hazard model. triglycerides> 150, current to account for differing lengths of tbllow-up ). 
smoking, 4th quartile of 
fibrinogen and diabetes good data used for comparison within DM 
duration >20 y. populations. 
Lee et al. Risk Ratios Proportional hazards age Family histOiy Rating: I I 
2004[11] Incidence and death rates regression. sex Trigylcerides 
per I ,000 person-years race Statins 
Kaplm1-Meier survival "Inspection of test center EtOH use 
curves. empirical cumulative 
hazards plots [log- Baseline levels of: 
log( survival function) smoking 
versus log (time) physical activity 
across diabetes and HDL 
MI categories] Total cholesterol 
indicated that the SBP 
proportional hazards ,8-blocker use 
assumption was ACEiuse 
justified" other anti-HTN med 
use 
Natarajan et al. Incidence rate Proportional hazards age Family Histmy Rating: II 
2003[13] Hazards Ratios model. HTN Medication Use 
smoking Triglycerides 
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Bootstrap resampling serum cholesterol 
was used to compare BMI (did not need to adjust by 
the CHD and sex because ran 2 analyses). 
diabetes proportional 
hazards regression 
coefficients on the 
risk of death from 
CHD. 
Hu, et al. 2005 ( l) baseline only Cox proportional Age (via separate analysis) LDLorHDL Rating: II 
[17] (2) incident only hazard models. Study year Medication use 
BMI Family History 
MOJtality Rates SBP EtOH 
Hazard Ratios Total Cholesterol Race 
Smoking 
Reference group was the 
subjects with DM only. 
2 sided p-value of <0.05 
Juutilainen et al. Difference in cumulative Cox hazards models. Age (via separate anaylsis) Medication use Rating: II 
2005 [19] survival between groups Sex Family history 
area of residence EtOH 
Hazard Ratios snioking status Race 
hypertension 
Reference group was total cholesterol 
nondiabetic subjects with HDL cholesterol 
prior evidence ofCHD. Log ofTriglycerides 
Simons and Hazard Ratios Cox proportional Age unsure Rating: III: carmot fmd what risk factors were 
Simons 1998 hazards model Sex controlled for 
[20] "other cardiovascular risk 
factors" 
Lotufo et al. Relative Risks (prospective Cox Proportional Age cholesterol and high blood Rating: III 
2001 [21] study design) Hazards Model BMI pressure - authors state that 
Smoking status they included these in a 
Reference group = people vigorous exercise secondary model and the 
without DM or CHD alcohol intake results were similar to those 
of the primary model. 
Medication use 
Family History 
Wannamethee et Relative Risk (prospective Cox Proportional age HTN Rating: 111 
al. 2004 [22] study design) Hazards Model smoking status Cholesterol 
social class Medication use 
Kaplan-Meier survival BMI Family History 
curves physical activity 
alcohol intake 
Whiteley et al. Hazard Ratios Cox Propottional age Medication use Rating: II 
2005 [23] Hazards Model smoking habit Family History 
Kaplan-Meier survival blood pressure EtOH 
curves. senun cholesterol 
BMI 
Referent group = subjects social class 
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with CHD only 
Vaccaro et aL Hazard Ratios Cox Proportional age Medication use Rating: 11 
2004 [24] Hazards Model race (white/nonwhite) Family History 
income EtOH 
serum cholesterol level LDLorHDL 
SBP 
cigarette smoking status 
(smoker/nonsmoker) 
Becker 2003 [25] Hazard Ratios . Cox Proportional age Medication use (even had Rating: II I (references ofHu Hazards Model smoking status data for this) ' 
2005) HTN Family History 
LDL 
HDL 
Triglycerides 
Natarajan et aL Age adjusted mortality Cox Proportional age Medication use Rating: II 
2005 [26] curves for the different study Hazards Model race Family History 
groups (tested equality by a HTN HDLorLDL 
Wald statistic) smoking hormone therapy 
Total cholesterol 
Hazard Ratios BMI 
(tested menopausal status but 
was not significant so was not 
included in final model. 
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Internal Validity Summary Table 
Study Potential for Potential for Potential for Overall 
Selection Bias Measurement Bias Confounding Internal 
Validity 
(Poor, Fair, 
Good) 
Hu et al II II III Fair 
200lfll 
Booth et al. fatal flaw fatal flaw fatal flaw Poor 
2006[3] 
Cho et al. II II III Fair 
2002[4] 
Eberly, et al. II I I Good 
2003 ~[5] 
Evans, Wang, fatal flaw II fatal flaw Poor 
and Morris 
2002. [7] 
Haffner et al. II I II Fair 
1998[8] 
Howard et al. III I fatal flaw Poor 
2006[10] 
Lee et al. II I II Fair 
2004[11] 
Natarajan et III II II Fair 
a!. 2003[13] 
Hu, et al. II II II Fair 
2005[17] 
Juutilainen et II I II Fair 
a!. 2005 [19] 
Simons and fatal flaw III III Poor 
Simons 1998 
[20] 
Lotufo et al. II II III Fair 
2001 [21] 
Wannamethee I III III Fair 
et al. 2004 
[22] 
Whiteley et II Ill II Fair 
a!. 2005. [23] 
Vaccaro et al. II \III II Fair 
2004 [241 
Becker 2003 II III II Not applicable 
[25] 
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Results Table 
Study Results• Power Overall Extemal Validity to 
CHD events CHD mortality CVD events CVD mm1ality Overall Mot1ality Intemal typical U.S. Patient 
Validity Population 
Hu eta!. DM no Ml N/A Baseline only NIA Baseline only Baseline only 3.12 Power limited Fair Poor for overall 
2001[1] compared to those ~ 7.48 (6.30- 6.59 (5.69-7.63) (2.83-3.44) for baseline population 
without either 8.89) Baseline and Baseline and f/up = measurement of 
condition Baseline and f/up ~ 4.86 2.44 (2.27-2.63) onlyCHD Fair for female subgroup 
f/up ~ 5.65 (4.27-5.52) group (wide of overall population 
(4.83-6.60) CI). 
MlnoDM NIA Baseline only NIA Baseline only - Baseline only 2.55 Only women, not 
compared to those ~ 8.15 (6.25- 6.58 (5.19-8.36) (2.12-3.07) generalizable to men 
without either 10.6) Baseline and Baseline and flup = 
condition Baseline and f/up ~ 7.46 2.58 (2.33-2.87) Nurses = more health 
flup = 10.7 (6.43-8.66) conscious, medically 
(9.03-12.6) knowledgeable, and 
greater access to health 
care than general 
population. 
Note that baseline analysis 
only includes people with 
long duration of DM (<::20 
yr) 
Used "old" definition of 
DM instead of fasting of<:: 
126 mg/dL. 
Cho et al. DM no MI NIA Baseline only N/A Baseline only - Baseline only- 1.91 N/ A for CHD or Fair Poor for overall 
2002[4] compared to those ~ 3.84 (3.12- 3.34 (2.80-3.99) (1.70-2.15) CVD events population. 
without either 4.71) Baseline and Baseline and f/up = 
condition Baseline and f/up = 2.75 1.76 (1.58-1.96) good for total Fair for male subgroup of 
llup ~ 3.37 (2.29-3.30) mortality overall population. Racial 
(2. 72-4.17) issues. More well 
MlnoDM NIA Baseline only NIA Baseline only - Baseline only 2.23 educated and better access 
compared to those ~ 7.88 (6.86- 5.63 (4.97-6.39) (2.03-2.45) to medical care. 
without either 9.05) Baseline and Baseline and f/up = 
condition Baseline and f/up ~ 5.51 2.07 (1.90-2.25) 
flup = 8.39 (4.88-6.23) 
(7.29-9.65) 
Eberly, et DM no NF-CVD NIA HR: 1.62 N/A HR: 1.51 (1.31- HR: 1.49 (1.34-1.64) N/ A for overall Good Poor for overall 
a!. 2003 [5] compared to those (1.36-1.93) 1.75) outcomes population because no 
without either women in study. 
condition Unknown for 
NF-CVDnoDM N!A HR: 3.05 NIA HR: 2.66 (2.30- HR: 1.92 (1.71-2.15) total mortality Fair for men: these men 
compared to those (2.58-3.60) 3.07) ranked by dm were more high risk and 
without either status. motivated to take control 
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condition of their health than the 
withNF~CVD N/A HR' 1.88 N/A HR, 1.76 (1.45- HR' 1.29 (1.12-1.49) overall population 
only compared to (1.51-2.34) 2.12) (willing to change 
those dm only HR by dm status: smoking status, diet, and 
(referent group) men with to come in for annual 
Hypoglycemic Agent visits). Only 4~9% 
(HGA) use' 0.93 African American. 
(p=0.54) 
men with glucose ;::: 
140 mg/dl no HGA: 
1.18 (p=0.09) 
men with glucose 
between 126~139 no 
HGA: 1.61 (u«0.01) 
Haffner et type 2 dm only reported HR 1.2 (0.6- repotted reported N/A power is Fair Fair 
al. !998[8] compared to those incidence rates 2.4) incidence incidence rates moderately low 
with only prior MI but did not rates but did but did not as evidenced by Really only comparable to 
(referent group) make/allow not make/allow this wideCI. DM patients that require 
this make/allow comparison (Due to only medication. 
comparison this having 69 
comparison participants mildly concerned that the 
with prior MI~ rates of CHD mottality 
no dm). are very high in Finland as 
compared to other areas of 
the world. 
Lee et al. prior Mlno RR 1.86 (1.35-2.56) RR 1.05 RR 1.82 (1.22- NIA power is Good 
2004[11] diabetes compared (combined these outcomes) (0.61-1.79) 2.72) moderate for 
to diabetes no CVD events. Population based study in 
prior MI (referent (n=312) the U.S. including both 
group) men and women. 
Natarajan et men with DM no HR- 1.7 (1.2- Power is Fair Good 
a!. CHD (Ml!AP/CI) 2.5), stratified moderately low 
2003[13] compared to those CHD risk for women as Includes both men and 
without either evidenced by women. 
condition wide Cis. 
men with Ml no HR s.o (3.6- Population sample from a 
DM compared to 6.9) U.S. city. 
those without 
CHDorDM Careful because all white 
men with AP/CI HR 3.2 (2.2- population. 
no DM compared 4.5) 
to those without 
CHDorDM 
women with DM HR 3.6 (2.2-
no CHD compared 5.9), stratified 
to those without CHD risk 
CHDorDM 
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women with Ml HR 3.1 (1.2-
no DM compared 7.6) 
to those without 
CHDorDM 
women with HR 1.3 (0.9-
AP/CinoDM 2.7) 
compared to those 
without CHD or 
DM 
Hu, et al. Men with only N/A HR-1.78 N/A HR 1.43 (1.16- HR 1.22 (1.03-1.44) Power is good Fair Good 
2005 [17] Baseline MI (1.39-2.27) 1.77) given nanow 
compared to only Cis. Captures all DM patients 
baseline OM thmugh sensitive 
(reference). measures. 
Women with HR 0.57 HR 0.63 (0.47- HR 0.55 (0.43-0.70) 
Baseline MI only (0.39-0.82) 0.84) Population based study. 
compared to 
women with 
baseline DM only 
_(reference) 
Men with incident HR 2.15 HR- 1.41 (1.16- HR- 0.95 (0.82-1.11) 
MI compared to (1.70-2.73) 1.71) 
men with incident 
DM (reference) 
Women with HR 1.65 HR 1.22 (0.98- HR 1.02 (0.84-1.23) 
incident MI (1.27-2.14) 1.53) 
compared to 
women with DM 
(reference) 
Juutilainen Men with dm only HR 0.85 HR 1.00 (0.64- HR 1.19 (0.80-1.75) when applicable Fair~Poor Fair 
et al. 2005 compared to non~ (0.53-1.37) 1.58) for men power 
[19] dm men with prior is fairly good Somewhat limited 
Ml (referent given narrow because we do not know 
group). CI. the demographics of the 
Men with dm only HR -1.50 HR 1.40 (0.99- HR 1.56 (1.19-2.05) individual comparison 
compared to non~ (1.01-2.22) 1.99) However power groups (only the overall 
dm men with any is limited for demographics as obtained 
prior CHD comparison of from the 1998 Haffner 
(referent group). priorMI in study[8]) 
Women with dm HR-1.91 HR 2.89 (0.92- HR 1.64 (0.81-3.35) women 
only compared to (0.6-6.08) 9.11) (although 
non-dm women heavily skewed 
with ptior MI toward 
(referent group) significance) 
Women with dm HR- 3.52 HR 4.43 (2.56- HR 2.72 (1.89-3.92) 
only compared to (1.83-6.79) 7.68) 
non~dm women 
with any prior 
CHD (referent 
group) 
. -
---
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Lotufo et al. DM only no CHD RR 2.9 (2,3- RR- 2.1 (1.9-2.4) N/A Fair Poor for overall 
2001 [21) compared to those 3.7) population. 
without DM or 
CHD Fair for men. 
CHD only no OM RR 5.4 (4.7- RR 2.2 (2.0-2.4) 
compared to those 6.2) Population consisted of 
without DM or only men that were health 
CHD professionals = more 
health conscious, 
medically knowledgeable, 
and greater access to 
health care than general 
population. 
Also, > 90% of 
participants were white so 
these may not be 
generalizable to other 
races. 
Wannameth Angina only RR 0.92 RR 0.79 RR 0.48 RR 0.73 (0.48- RR 0.81 (0.59-1.11) power seems Fair Poor for overall 
ee eta!. referent group = (0.61-1.39) (0.48-1.30) (0.20-0.90)) 1.10) relatively good population (study aU 
2004 [22) dmnoCHD given narrow males) 
Cis- although 
MI only referent RR-1.59 RR-1.47 RR-0.87 RR- 1.42 (0.98- RR- 1.25 (0.94-1.67) we may see a Fair for male population 
group = dm no (1.09-2.31) (0.94-2.29) (0.51-1.49) 2.05) different answer (subjects taken from 
CHD if power was general population, 
increased due to although all of the 
comparisons participants had access to 
between MI the NHS whereas not all 
only and OM Americans have access to 
only barely health care coverage and 
being there is a lack of racial 
insignificant. diversity). 
Whiteley et Men withDM HR 1.17 HR 1.20 (0,92-1.56) Power for men Fair-Poor Good for both men and 
al. 2005 only compared to (0.78-1.74) is relatively women, seemed to be 
[23) men withCHD good given relatively representative 
only (referent 
gro~p) narrow Cis of a general population. 
Women with OM HR-1.97 HR 1.80 (1.37-2.35) 
only compared to (1.27-3.08) 
women with CHD 
only (referent 
group). 
Vaccaro et Men with prior Ml HR 1.37 HR 1.25 (1.16- HR 0.97 (0.92-1.03) good power for Fair Good for U.S. men-
a!. 2004 only compared to (1.26-1.48) 1.34) negative studies participants came from a 
[24] men with prior variety of U.S. towns in a 
DM only (referent stroke only variety of populations. 
group). HR~0.61 
(0.46-0.80) Poor for overall U.S. 
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population because did 
not study women. 
Natarajan et MenwithRDM HR 0.7 (0.3- Power moderate Fair·Good Overall Good 
al. 2005 only compared to 1.3) as seen by the 
[26] men with prior Ml nanuw Generated as U.S. 
only (referent confidence population sample. May 
I group) intervals. not apply to patients with 
Men with LDM HR 0.8 (0.4- mild diabetes that would 
only compared to 1.4) not have been diagnosed 
men with prior Ml as having DM in the 70s 
only (referent or those with recently 
group) diagnosed milder disease. 
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